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 ABSTRACT 
Imaging is essential in the diagnostics and medicine of today. The development of new 
contrast agents is important for obtaining specific information from images and to 
distinguish disease. Microbubbles (MB) have previously been introduced as a contrast 
agent for ultrasound. By incorporating super paramagnetic iron oxide nanoparticles 
(SPION) to the polymer matrix of the MB or between its shell layers we obtain a 
contrast media for Magnetic Resonance Imaging (MRI); while functionalizing the MB 
by ligands for labeling with 99mTc enables imaging using Single-Photon Emission 
Tomography (SPECT). The use of hybrid SPECT- and Computed Tomography (CT) or 
MRI systems enables fusion of the images from the different modalities to obtain 
SPECT/CT or SPECT/MR images. In the research underlying this thesis we 
investigated the preclinical characteristics, biodistribution and kinetics of several types 
of MB in Sprague Dawley rats by injecting single- and multiple layer SPION MB as 
well as ligand functionalized- and SPION MB labeled with 99mTc. The results obtained 
from imaging was correlated and compared to the histopathology of MB findings in 
organs. Moreover, mice were injected with Alexa-680 Vivo Tag labeled MB for 
imaging using a pre-clinical In Vivo Imaging System (IVIS)/µCT.  
 
Sprague Dawley rats (300  ± 50 g) were injected with single layer SPION-, multiple 
layer SPION-, 99mTc-labeled ligand functionalized diethylenetriamine penta-acetic acid 
(DTPA)-, thiolated poly(methacrylic acid) (PMAA)-, chitosan-, 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA)-, NOTA-SPION- or DTPA-SPION MB 
intravenously (i.v.) through the tail vein. The rats injected with SPION MB were 
scanned using MRI, while the rats injected with 99mTc-labeled DTPA-, PMAA-, 
chitosan- or NOTA MB were scanned using SPECT/CT. The rats injected with NOTA-
SPION- or DTPA-SPION MB were co-registrated using SPECT/CT and MRI. The 
organs from rats injected with the nuclear medicine marker were removed post mortem 
and measured for radioactivity. The rats injected with SPION MB were sacrificed and 
their organs were removed post mortem for histopathology examination using Perls’ 
Prussian blue staining to show iron content and immunohistochemistry (IHC) to 
visualize macrophage uptake of MB.  
Mice (30 ± 5 g) were injected with multiple layer fluorescence Alexa-680 MB and 
imaged using IVIS. Their organs were removed post mortem and examined using 
pathology and the fluorescence of MB was visualized under the microscope.  
 
The uptake of MB was mainly seen in the lungs and liver 1-2 h post-injection, while the 
main distribution of MB at 24 h post-injection was seen in the liver. In conclusion the 
MB matrix can be functionalized by ligands, labeled by SPION, 99mTc and fluorescence 
Alexa-680 Vivo Tag to enable its visualization in vivo using multimodal imaging 
SPECT/CT, SPECT/MRI or IVIS/µCT. Furthermore we have shown that MB can be 
loaded with cytostatic- or inflammatory drugs for theranostics. Future studies regarding 
MB should address toxicity and efficiency in drug loading and delivery. 
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1 INTRODUCTION 
 
1.1 BACKGROUND  
Imaging is essential in diagnostics today. The combination of imaging modalities to get 
the most relevant characteristics from each modality is of great interest for future 
clinical applications. Combining dual or triple imaging methods with short time and 
space lapse in hybrid systems supports the growing interest in in vivo multimodal- and 
targeted imaging. Furthermore, contrast agents can improve the distinction and 
identification of different tissues and pathologic structures since they provide an 
increase, such as a positive contrast, or decrease, such as a negative contrast, in images 
[1-3]. There is no contrast agent for combined imaging available today. Thus, exams 
using different modalities are normally carried out on different days, which might 
prolong the time it takes to obtain a diagnosis by several weeks. The development of 
multimodal contrast agents could enable exams to be carried out during a single day, 
which would be beneficial to the individual patient as well as to the health care system 
by shortening the time to diagnosis as well as leaving more beds and equipment free for 
other patients [4-8]. When developing a new contrast agent, it is important to determine 
its pharmacokinetic properties and to investigate its biodistribution over time in animal 
models before testing the substance in humans [9-16]. In the current thesis we 
investigate a potential new delivery system of a tri-modality-suited contrast agent 
consisting of polymer shelled, poly(vinyl) alcohol microbubbles (MB).The polymer 
matrix has an amazing property in that it can be functionalized with several ligands 
[17], i.e. diethylenetriamine penta-acetic acid (DTPA), 1,4,7-triazacyclononane-1,4,7-
triacetic acid  (NOTA), poly(methacrylic) acid (PMAA) and chitosan to bind 99mTc, a 
radiotracer which enables the MB to be visualized using Single-Photon Emission 
Computed Tomography (SPECT) [18]. Moreover, the MB can be incorporated with 
nanoparticles such as superparamagnetic iron oxide nanoparticles (SPION), either 
physically bound inside the shell, chemically bound to the MB PVA matrix using 
covalent bonding or trapped in between the layers of the MB shells [19]. SPION 
enables the magnetic SPION MB to be used as a contrast agent for magnetic resonance 
imaging (MRI) [20, 21]. MRI is a non-invasive, high resolution diagnostic method that 
provides information on morphological and physiological changes of internal organs 
over time. Imaging and measurements can be repeated on the same subject, thereby 
reducing inter-variability effects and hence the number of subjects required in a study. 
This in turn saves time and money as well as animals, according to the three R:s,   
Replace, Reduce and Refine. The capacity of the MB system for the functionalization 
of multiple nanoparticles and/or ligands enables its use as a multimodal imaging agent 
by visualizing both function and anatomy in one image using hybrid SPECT/Computed 
tomography (CT) or SPECT/MR systems. Pre-clinical studies are warranted in the 
development of new contrast agents before reaching the clinical phase in 
pharmaceutical development, and several animal studies are necessary before trying the 
substance in humans. The development of pharmaceuticals moves from an 
exploratory/preclinical phase in animals to human I-IV studies. The exploratory phase  
 2 
include pharmacokinetics-, safety- and toxicity studies of the pharmaceutical in mice, 
rats and larger animals such as pigs before reaching the clinical phase [22-25].  
The present studies were carried out in the preclinical phase in rats and mice. Ligand 
functionalized- and SPION MB were injected intravenously (i.v.) into Sprague Dawley 
(SD) rats to determine their biodistribution, biological fate and pharmacokinetics using 
fusion SPECT/CT/MR imaging. Moreover, the In Vivo Imaging System (IVIS) can be 
used in combination with MRI or CT to visualize the biodistribution of fluorescence 
MB such as Alexa-680 Vivo Tag labeled MB (Alexa-680 MB). In recent years, 
nanoparticles and micro vehicles such as microbubbles have become interesting targets 
for multimodal imaging and drug delivery. The MB and the developed imaging 
methods and protocols have a future potential for use in the imaging of tumors and 
cancers, in diagnostics and for inflammatory models. In my PhD thesis I have studied a 
potentially new, multifunctional contrast agent supporting multimodal imaging using 
MRI with a high spatial resolution, SPECT for quantitative imaging, CT for anatomy 
and IVIS for the preclinical work. The organ biodistribution obtained using multimodal 
imaging techniques was verified in the organs by histopathology and by the 
measurement of radioactivity in the respective organs post mortem. 
 
1.2 MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging (MRI) is considered state of the art in diagnostics and was 
originally used for imaging of lesions and pathologic structures since it has a high 
resolution for soft tissue. In contrast to CT, SPECT and PET, MR imaging requires no 
iodinated or radioactive contrast agents. MRI is free of biological hazardous materials 
and is a non-invasive technique. Due to its high spatial resolution, it was originally used 
mainly for brain imaging [26]. Originally, Raymond Damadian proposed nuclear 
magnetic resonance (NMR) scanning of patients to obtain a diagnosis [27]. He 
proposed that cancer and normal tissue can be distinguished using MRI, due to their 
different relaxivities [28, 29]. Damadian was followed by Paul Lauterbur, who 
published a new imaging method that was called Zeugmatography. This new technique 
generated the first 2D- and 3D MR images moving the application of NMR 
spectroscopy from a single dimension to a second dimension of spatial orientation. That 
became the foundation of today’s MRI technology [30-32]. Peter Mansfield, who later 
was awarded the Nobel Prize in medicine together with Paul Lauterbur, developed a 
mathematical technique that would allow scans to take seconds rather than hours. This 
technique also produced clearer images. NMR is the basis of MRI which involves the 
interaction between a static magnetic field and protons that align perpendicular to the 
magnetic field (ß0). In the MR scanner there are also three gradient magnets 
responsible for the ability of MRI to create “slices” of the body in the MR tomography. 
The nuclei of the hydrogen (H) atoms spin in one of two directions. By exposure of the 
external, static magnetic field of the MR scanner, β0, the spin of the nucleus takes one 
of two directions, anti-parallel or parallel. The difference of the vectors, the net 
magnetization vector M, is parallel to the static magnetic field.  
 
 
   3 
 
 
 
 
 
 
Figure 1. A Sprague Dawley rat (300 g) imaged prone using an in-house developed T2* 
sequence at 3 T (Siemens Trio, Siemens, Erlangen, Germany). MR signal intensity changed 
mostly in the liver over time from 10 min to 6 weeks compared to pre-injection. (A) pre- 
injection, (B) 10 min, (C) 1 h, (D) 24 h, (E) 48 h, (F) 1 week, (G) 2 weeks, (H) 4 weeks and (I) 
6 weeks post-injection. Published by Barrefelt et. al. in International Journal of Nanomedicine 
2013:8(1) pages 3241 – 3254. 
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When applying a radiofrequency (RF) using the coil, a transition takes place exactly at 
the Larmour frequency, ω0 = 42.58 MHz/Tesla:   
 
 ω0 = λβ0  (where λ = 42.57 MHzT-1) 
 
This will transfer energy to the precessing protons [33]. By turning off the RF pulse the 
excited nuclei return to their initial equilibrium state. The process of relaxation then 
generates a MR signal picked up by the receiver coils. The magnitude of this vector is 
an exponential function of time, the free induction decay (FID). The processes are 
recorded and reconstituted by the MR scanner to obtain gray scale images. 
 
The relaxation involves both T1 and T2 relaxation. T1 is the longitudinal relaxation 
from the excited state to the surrounding, denoted spin lattice relaxation time; which 
reflects nuclei falling back from the high to the low energy state and is the time for 63 
% recovery of a decreased longitudinal net magnetization (Mz). T2 (spin-spin 
relaxation) reflects the decay of transverse magnetization (Mxy) from the induced 
disappearance of transverse magnetization to the perpendicular plane (Mxy) by the 
dephasing of the spins. T2 is the decay of 37 % of the signal. T2 arises from the 
exchange of energy between spins wherein no energy is lost from the spin system, but 
the decay of magnetization arises from the loss of phase coherence of the precessing 
nuclei. 1/T2 is the transverse relaxation rate. 
 
The dephasing is eliminated by applying a 180 degree pulse. However, in gradient echo 
sequences there is no 180 degree refocusing pulse and the dephasing effects are not 
eliminated, which is why transverse relaxation in gradient echo (GRE) sequences is a 
combination of T2 relaxation and by the relaxation caused by magnetic field 
inhomogeneities caused by the air filled microbubble as in: 
 
1/T2* = 1/T2 + λΛB or 1/T2* = 1/T2 + 1/T2’ 
 
T2* is the rate of decay of phase coherence or decay of transverse magnetization and 
heterogeneities of the environment. T2* is faster than T2 due the inhomogeneity in the 
magnetic field. Furthermore, magnetic field inhomogeneities are either macroscopic 
and include deoxyhemoglobin in tiny veins, metallic implants, or microscopic such as 
paramagnetic contrast agents, blood or iron deposits or air tissue interaction such as in 
air filled MB [34]. Dephasing areas, lesions or structures are shown as dark areas on 
T2* weighted images. T2* decay starts with excitation and progression within time, 
and the longer the echo time (TE) the greater the signal loss because of more 
dephasing, a low flip angle, long TE and long TR. T2* weighted imaging is commonly 
used for MR perfusion or MR functional imaging. The loss of RF signal means loss of 
phase coherence, so called “dephasing”, which comes from the loss of spin-spin 
relaxation expressed by T2. This can be cancelled by a spin-echo maneuver in which a 
90º RF pulse is applied and serves to re-gather the transverse relaxation vectors to emit 
a strong signal [35]. In fluids, the T2 and T2* times will be longer and signal intensity 
lower, whereas in water based tissues such as muscle and fat they will be of 
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intermediate intensity. With shorter TEs, fluids lose their brightness. T2 is often called 
pathology scans.   
 
By injecting a rat by SPION MB and imaging it dynamically at different time points 
(Figure 1) we can calculate the concentration of SPION MB in the respective organs. 
By using several TE:s and measuring the signal intensity, with the least possible 
standard deviation, in a region of interest (ROI) on T2* weighted MR images and 
plotting the signal intensity towards the respective TE value we obtain graphs (Figure 
2). By plotting the logarithmic value of the signal intensities versus the TE values we 
obtain a straight line for each time point (Figure 3). The spin-spin relaxation time, T2 
star (T2*) is thus calculated as the negative slope of a semi-log plot of the signal 
intensities versus the TE:s. The slopes describes R2* (1/T2*), the relaxation rate, the 
amount of iron oxide at each time point. T2* or R2* can be calculated in agarose 
phantoms of known iron oxide concentrations and plotted to obtain a standard curve. 
R2* in rat liver (Figure 4) can then be correlated to the concentration, using the 
standard curve, and plotted versus time. Furthermore, pharmacokinetic calculations will 
enable the estimation of half-life, clearance, Cmax, Tmax and AUC of SPION MB by 
using MR imaging.  
 
 
Figure 2. Signal intensity versus TE pre- and post-injection of SPION MB in rat. The graph 
shows that by an increase of iron oxide in the tissue by time, a greater signal loss is obtained.  
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Figure 3. T2* is calculated as the negative slope of the semi-log plot of the signal intensities 
versus the TE values. The slopes describes R2* (1/T2*), which is the amount of iron oxide in 
the liver tissue of a rat at different time points pre- and post-injection of SPION MB 
. 
 
 
Figure 4. Dynamic 3 T MR imaging (Siemens Trio, Siemens, Erlangen, Germany) of R2* (s-1) 
versus time (h) in rat liver (blue), pre- and post-injection of multiple layer SPION MB. ROI 
measurements and calculated R2* in kidney (red), brain (green) or muscle (lilac) shows no 
significant uptake of SPION MB.  
 
 
 
   7 
1.3 X-RAY COMPUTED TOMOGRAPHY 
A new era in medicine was introduced when Wilhelm Röntgen captured the first X-ray 
images of his wife’s hand in 1895 [36]. X-ray computed tomography (CT) has since 
been intensively used in many applications such as fusion imaging in combination with 
SPECT or positron emission tomography (PET) imaging. CT provides anatomical 
information which can be overlaid on functional images to aid in the interpretation of 
organ uptake of radiotracer in nuclear medicine images. The CT technique is based on 
the fact that different tissues have different levels of X-ray absorption, which generates 
diverse contrast intensities on images. Tissues that differ as little as 1 % from each 
other in physical density can be distinguished on CT images. Barium or iodine contrast 
agents are used clinically for the detection of contrast on CT images. Hounsfield units 
(HU) is the scale for radiodensity. Furthermore, exciting future developments could be 
possible in the use of new CT contrast agents such as Gold (Au) nanoparticles, utilizing 
the property of Surface Plasmon Resonance (SPR). Au can be attached to polymers and 
MB and has been shown to have better contrast properties than commercial CT contrast 
agents [37]. This is an exciting and emerging field yet to be further explored.  
 
1.4 NUCLEAR MEDICINE IMAGING 
 
1.4.1 Dynamic Planar Scintigraphy 
Scintillation cameras/gamma cameras consist of a collimator, two detectors made of 
NaI (3.67 g/cm3) crystals (33x43 and 37x59 cm) with thicknesses between 0.64 and 1.9 
cm); which efficiently produce light photons (one photon per approximately 30 keV) 
upon interaction with γ-rays in the presence of Thallium (T1), positioning circuit. 
Photomultiplier (PM) tubes consisting of a light-sensitive photocathode at one end, 
metallic electrodes in the middle and an anode at the other end, pre-amplifiers and 
linear amplifiers, PHA and display [38]. The scintillation camera, Symbia True Point 
16 hybrid system, Siemens, Erlangen, Germany, used in this thesis consist of a parallel 
hole collimator enabling high-resolution and high-sensitivity imaging with the highest 
resolution at the collimator face. Dynamic planar scintigraphy can be used to follow the 
uptake of a gamma-emitting heavy radioisotope/radioactive tracer such as 99mTc, 123I, 
67Ga and 111In over time. It can be visualized on dynamic gamma camera graphs, where 
the number of counts (Cnt) as measured in circular regions of interest (ROIs), placed in 
the organs on images, are plotted versus time (min). Anger developed the first clinically 
used scintillation camera to use PMT tubes for the detection of exactly where the flash 
of light occurs [39, 40].  
 
1.4.2 Single-Photon Emission Computed Tomography  
Tomography images are obtained by imaging the patient from different angles such as 
anterior, posterior and lateral, and by applying rigorous mathematical algorithms to 
reconstruct the images. The SPECT system utilized in this thesis consists of a gamma 
camera with two heads mounted on a gantry and on-line computers for acquisition and 
data processing. The detector heads rotate around the long axis of the patients in small 
angle increments for a total of 360°. The data is stored in 128 x 128 matrices for the 
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reconstruction of transverse, sagittal and coronal images. The limitation of scintillation 
cameras is that they depict images of three-dimensional activity in two-dimensional 
displays [41].   
 
1.5 FUSION IMAGING: SPECT/CT, SPECT/MRI, IVIS/µCT OR IVIS/MRI 
Hybrid imaging is carried out using several modalities, combining the images by fusion 
imaging to obtain SPECT/CT, SPECT/MR, IVIS/CT or IVIS/MR images. Fusion 
imaging can localize lesions, tumors or uptake of radioactive- or fluorescent tracer 
injected into the patient or animal [18, 42, 43]. The CT and MR images give anatomical 
information providing an organ atlas and structural information, whereas the SPECT 
and image gives functional information and characterizes functional abnormalities [44]. 
Fusion imaging is also helpful when using IVIS in preclinical studies to show the 
uptake location and biodistribution of fluorescent probes [43, 45]. The IVIS image is 
fused with an image acquired using µCT.  
 
1.5.1 99mTc as a Radioactive Tracer  
99mTc is the most commonly used clinical radiopharmaceutical [46-51]. It has favorable 
characteristics with a relatively short half-life of 6 h and a small amount of electron 
emission with a minor radiation dose to the patient. The monochromatic 140 keV 
photons are easily collimated, resulting in images with a high spatial resolution to the 
patient. When eluted from the generator 99mTc has oxidation state +VII, which is why 
reduction to a lower oxidation state is required before labeling any other compounds. 
Stannous chloride (SnCl2·2H2O), dithionite or ferrous sulfates are some examples of 
reducing agents. After reduction, 99mTc is chemically reactive with various chelating 
compounds, donating electrons to form co-ordination bonds with the reduced 99mTc 
carboxyl- (-COO-), hydroxyl (-OH-), amine- (-NH2) or thiol (-SH) groups  existing in 
chelating agents. 99mTc labeled compounds are thereafter injected into animals or 
patients, where they emit photons that can be imaged using gamma camera and SPECT 
[18, 52]. In this thesis I used 99mTc labeled MB, imaging their uptake and 
biodistribution using SPECT for anatomy, and co-registrationd to get fusion 
SPECT/CT and SPECT/MR images which can localize the organ or region of uptake 
and visualize biodistribution [18].   
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Figure 5. Multimodal imaging using fusion SPECT/MRI. SPECT enables the functional 
visualization of MB in the lungs 1 h post-injection (A) and in the liver and kidneys 24 h post- 
injection (B); while MRI enables the visualization of an anatomical image of the rat and 
visualizes SPION MB in the liver 1 h post-injection (A) and 24 h post-injection (B), Published 
by Barrefelt et. al. in EJNMMI Research 2013, 3(1):12. 
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1.6 FLUORESCENCE IMAGING, IN VIVO IMAGING SYSTEM 
Fluorescent dyes attached to MB or other vehicles are excited by light in a specific 
region, and are therefore suitable for imaging. Alexa-680 Vivo Tag (Perkin Elmer, 
USA) or fluorescein isothiocyanate (FITC) can be covalently attached to the polymer 
matrix of the MB, and the fluorescent MB can be studied under the microscope or in 
an IVIS system in animals. In combination with co-registration using CT, µCT and/or 
MRI, anatomical information can be obtained to show the exact organ location of 
uptake of the fluorescent marker. The IVIS® Spectrum, uses an optical imaging 
technology to facilitate non-invasive longitudinal monitoring of biodistribution and 
disease progression in living animals. An optimized set of high efficiency filters and 
spectral un-mixing algorithms makes it possible to take advantage of bioluminescent 
and fluorescent reporters across the blue to near infrared wavelength region. It also 
offers single-view 3D tomography for both fluorescent and bioluminescent markers 
that can be registered with our multimodality module to other tomographic 
technologies such as MRI, CT or SPECT/PET. For advanced fluorescence pre-
clinical imaging, the IVIS Spectrum has the capability to use either trans-illumination 
(from the bottom) or epi-illumination (from the top) to illuminate in vivo fluorescent 
sources. 3D diffuse fluorescence tomography can be performed to determine source 
localization and concentration using the combination of structured light and trans-
illumination fluorescent images. The instrument is equipped with 10 narrow band 
excitation filters (30 nm bandwidth) and 18 narrow band emission filters (20 nm 
bandwidth) that assist in significantly reducing auto fluorescence by the spectral 
scanning of filters and the use of spectral unmixing algorithms. In addition, the 
spectral unmixing tools allow the researcher to separate signals from multiple 
fluorescent reporters within the same animal. The basic principle of fluorescence is 
illustrated in a Jablonski diagram [53].  
 
1.7 TARGETING 
When studying a disease using an animal model, targeting is essential in directing the 
MB vehicle or nanoparticle to the site of disease. Streptavidin based microbubbles or 
nanoparticles can be used for tumor targeting with anti-Her2 Herceptin antibody, a 
biotinylated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator 
labeled with 111In for nuclear imaging as well as a biotinylated Cy5.5 fluorophore [54]. 
Anti-Her2 Herceptin antibody is widely used in the clinic in combination with 
chemotherapy for targeting and treatment of breast cancer [55].  
 
Streptavidin can be attached to MB for further coupling of radioactive markers, 
fluorescence dyes, chelators or antibodies against inflammatory markers such as 
Vascular Cell Adhesion Molecule (V-CAM) and Intercellular Adhesion Molecule 
(ICAM), which could target inflammation [56, 57]. SPION MB have been targeted by 
Streptavidin, and work is performed to enable drug delivery to inflammatory tissue 
such as inflamed muscle.  
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1.8 THERANOSTICS AND DRUG DELIVERY 
Despite extensive research during the past decades, cancer is still the second largest 
cause of death in developed countries. Cytostatic drugs are the corner stone of cancer 
treatment; however, these drugs are non-selective and have several side effects 
including CNS toxicity, growth disturbances in children, liver toxicity and kidney 
insufficiency. In the present work we investigated a new theranostic delivery system for 
chemotherapy by incorporating cytostatics into MB and microcapsules (MC). The use 
of polymer vehicles for theranostic devices is a promising future application of ligand 
functionalized SPION MB [58, 59]. This approach combines the imaging properties of 
MB by using SPECT/MRI with the MB:s ability to bind ligands and target disease by 
incorporating substances into their polymer matrix; such as doxorubicin, busulfan or 
dexamethasone. This enables the use of MB for theranostic purposes [60-70].  
 
1.9 TRANSMISSION ELECTRON MICROSCOPY 
Transmission electron microscopy (TEM) is an excellent tool for imaging and 
measuring the size of nanoparticles [20, 21]. Instead of light it utilizes electrons passing 
through an ultrathin specimen. An image is obtained from the interaction of electrons 
passing through the specimen. These electrons have a lower wavelength, which allows 
a resolution so high that even a single column of atoms can be detected. A "light 
source" at the top of the microscope emits the electrons that travel through vacuum in 
the column of the microscope. Instead of glass lenses focusing the light in the light 
microscope, the TEM uses electromagnetic lenses to focus the electrons into a very thin 
beam. The electron beam then travels through the specimen. Depending on the density 
of the material present, some of the electrons are scattered and disappear from the 
beam. At the bottom of the microscope the unscattered electrons hit a fluorescent 
screen, which gives rise to a "shadow image" of the specimen with its different parts 
displayed in varied darkness according to their density. The image can be studied 
directly by the operator or photographed with a camera. Microbubbles, nanoparticles 
and SPION patterns can be visualized using TEM. Micro- and nano vessel size can then 
be calculated [20, 21].  
 
1.10 PERLS’ PRUSSIAN BLUE STAINING AND 
IMMUNOHISTOCHEMISTRY 
Perls’ Prussian blue staining is commonly used to verify the presence of iron content in 
tissue and it can even distinguish single granules of iron in cells. By using 
haematoxylin and eosin (H&E) staining one can detect iron as brown pigments in tissue 
sections. However other pigments can show a similar color why haemosiderin should 
be differentiated from other brown pigments using the Perls’ Prussian blue 
histochemical staining technique [20, 71, 72]. Moreover to show and visualize that 
SPION MB can be taken up by macrophages, CD68+ macrophages can be detected 
immunohistochemically [20]. This is shown in Figure 6.  
 
 
 12 
 
Figure 6. Intracellular localization of fluorescent SPION microbubbles inside labeled 
macrophages. A primary antibody against CD68 (red) confirms phagocytosis of the 
microbubbles (green) by macrophages in the lungs. The nuclei were stained blue using DAPI. 
The size bar represents 25 μm. The upper left part of the image is higher magnification with 
the size bar of 10 μm, Barrefelt et al. International Journal of Nanomedicine 2013:8(1) pages 
3241 – 3254. 
 
1.11 CONTRAST AGENTS 
 
1.11.1 Microbubbles 
In the current thesis, 3 µm single- and multiple layer PVA MB were used as a new 
contrast agent for multimodal imaging and theranostic applications. The thesis was 
carried out as part of the EU FP7 project 3MiCRON. Historically, MB were developed 
and used for ultrasound imaging due to their echogenicity after application of US 
waves [73-75]. Since the polymer matrix in MB is capable of functionalizing ligands 
for further binding of nuclear medicine markers and fluorescent markers, trapping and 
binding SPION and nanoparticles in their shell, MB can be used as an imaging vehicle 
for SPECT and MRI [17, 18, 20]. Tailoring the MB further by their size and 
lipophilicity might change their biodistribution, enabling imaging and drug delivery to 
several or different organs.  
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1.11.2 SPION 
Several studies have shown that SPION can be easily tailored with targeting moieties, 
fluorescent dyes or therapeutic drugs [76]. SPION can also be used as potential anti-
cancer agents for tumor therapy due to their cytotoxicity and/or their ability as drug 
carriers [77-79]. SPION with a size between 10 and 100 nm has a long enough 
circulation time to extravasate into the extra cellular space of tumors [80]  and can be 
used in cancer imaging [81]. Polymer coated SPION have been reported to be useful as 
carriers for pharmaceutical drugs in slow release preparations and for magnetic 
hyperthermia [82, 83]. Iron particles from degrading SPION are eliminated in the body 
either through uptake by reticuloendothelial system (RES) cells (particles larger than 20 
nm) or via renal filtration (particles with a hydrodynamic size of less than 5.5 nm) [81].  
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2 AIMS OF THE THESIS 
 
2.1 GENERAL AIM 
 
The aim of this thesis is to study the biodistribution and kinetics of microbubbles (MB) 
as a contrast- and theranostic agent using multimodal imaging. 
 
 
2.2 SPECIFIC AIMS 
 
1. To study the physical properties of MB as a MR contrast agent.  
 
2. To study the pharmacokinetics and fate of single layer SPION MB as a 
contrast agent using MR imaging.  
 
3. To study the biodistribution of ligand functionalized-, 99mTc labeled-, single- 
or multiple layer MB or SPION MB as a contrast agent in the rat using 
multimodal fusion imaging, SPECT/CT and SPECT/MRI. 
 
4. To study the biodistribution, kinetics and biological fate of multiple layer 
SPION MB in rat organs. 
 
5. To study the biodistribution of fluorescent Alexa-680 MB using multimodal 
fusion imaging, in vivo imaging system (IVIS)/µCT. 
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3 MATERIALS AND METHODS 
 
3.1 MICROBUBBLE SYNTHESIS (STUDY I-V) 
 
3.1.1 The Formation of Microbubbles (Study I, II, III, IV, V) 
PVA shelled MB synthesis has been described elsewhere [84]. The synthesis can be 
summarized as follows: Poly (vinyl) alcohol (2 g); PVA 70K; (P1763, Sigma-Aldrich) 
was added to 100 mL of Milli-Q water. The suspension was stirred at 80°C to allow 
PVA dissolution. Sodium metaperiodate (0.19 g) was added to the solution and the 
mixture was stirred (1 h, 80°C). The solution was cooled to room temperature, with 
continuous stirring. The cross-linking reaction was carried out under vigorous stirring 
at room temperature (2 h, 8000 rpm) by an Ultra-Turrax T-25 equipped with a Teflon-
coated tip. Floating MB were separated from solid debris and washed with Milli-Q 
water. 
 
3.1.2 Formation of Single Layer Poly(Vinyl) Alcohol Microbubbles 
with Embedded SPION in the Shell (SPION MB) (Study I, II) 
The synthesis of the PVA SPION MB has been reported previously [85]. Briefly, iron 
(II, III) oxide (Fe3O4) nanoparticles (SPION) with an average size of 8-10 nm were 
manufactured by mixing two acidic iron containing solutions, FeCl3·6H2O and 
FeCl2·4H2O. The SPION were co-precipitated under vigorous stirring and addition of 
NaOH and thereafter collected using a magnetic bar and re-suspended in Milli-Q water. 
PVA was oxidized in Milli-Q water using sodium metaperiodate (1 h at 80°C) [84]. 
The PVA microbubbles containing SPION (20 mg/ml) were formed by adding the re-
suspended SPION to the solution containing the oxidized PVA under stirring using 
Ultra Turrax (IKA-2000, Staufen, Germany), (8000 rpm, 2 h) to obtain SPION MB.  
 
3.1.3 Chitosan Oxidation and Coupling to the Surface of Single 
Layer MB (Study III) 
The metaperiodate ion, IO4-, cleaved the C2-C3 bond of the glucosamine residue of 
chitosan, which led to the formation of a di-aldehyde with the elimination of an 
ammonia molecule. However, the N-acetylated amino groups at the C2-position of the 
chitosan backbone (15 %) prevented the oxidation cleavage by metaperiodate. For the 
oxidation reaction, chitosan was dissolved in 1 % (w/v) distilled and de-mineralized 
water/HCl (pH = 4.5) and was thereafter mixed with a given amount of NaIO4 (dark 
condition). A 2-fold molar excess of chitosan in relation to NaIO4 was used. After 24 h 
the solution was dialyzed (dialysis membrane, MWCO of 2,000) against deionized 
water (pH = 4.5), lyophilized and stored as a freeze-dried powder. The oxidation that 
leads to chain de-polymerization as a side reaction increased the low solubility of 
chitosan in water and prevented cluster formation of the MB. The freeze-dried 
periodate oxidized chitosan was dissolved in D2O (5% w/w TMS) at a concentration of 
5 mg/mL. The resulting solution was subjected to 1H-NMR examination and the degree 
of oxidation was calculated considering the integral of the C2-resonance at 3.00 ppm, 
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taking as reference the signal of the tri-methyl group of TMS at 0.0 ppm (9 H, TMS tri-
methyl group). The oxidized chitosan was conjugated to MB by an acetalization 
procedure. The polymer was dissolved in Milli-Q water to a concentration of 1% (w/v). 
A sample of 20 mg aqueous MB suspension was added and the final volume was 
adjusted to 10 mL. The pH was carefully adjusted to 3.0 with 0.1 M HCl. The resulting 
suspension was stirred in the dark for five days at room temperature followed by 
extensive washing in separatory funnels and stored in Milli-Q water at 4°C. 
 
3.1.4 Aminoguanidine Coupling (Study III, IV, V) 
The MB suspension was centrifuged (30 g, 1 h) followed by removal of the subnatant. 
Aminoguanidine (5mg/mL) in HEPES buffer (0.1 M, pH = 8) was added and the 
suspension was kept on the shaker for 1 day. Afterward, the MB were washed three 
times. After each wash, the MB in the upper phase were separated by centrifugation (30 
g, 1 h) and the subnatant was removed.  Plain MB with a positively charged surface 
(amino groups) were obtained. The charged surface was necessary to further 
functionalize the MB by the different ligands: DTPA, PMAA, NOTA, NOTA-SPION 
and DTPA-SPION (Figure 1-I).  MB were visualized using confocal laser microscopy 
at a resolution of 550 x 550 µm (Figure 1-II) (Leica TCS SPE, Leica Microsystems 
GmbH, Wetzlar, Germany). Size distribution was determined using flow cytometry 
(Partec CyFlow, ML, USA). Analysis of size distribution was performed using forward 
scattering versus side scattering.  Figure 1-III shows DTPA-SPION MB.  
 
3.1.5 Grounding by the Layer by Layer (LbL) Method [86] (Study III, 
IV, V) 
Following the aminoguanidine (AG) grounding, the MB were coated using the layer by 
layer (LbL) technique and functionalized by different layers of poly(styrene)sulfonate 
(PSS) 70,000 / poly(ethylene) imine (PEI) 25,000 / PSS 70,000 / PEI 25,000 / PSS 
70,000. The coating solutions consisted of 2 g/L in 50 mM acetate buffer (pH = 5.6) 
and 0.2 M NaCl. After each layer was added, the MB were washed four times followed 
by centrifugation to separate the upper phase (30 g, 40 min). The subnatant was then 
removed. This was followed by addition of the next layer obtaining a layer by layer 
LbL MB [86]. 
3.1.6 Preparation of DTPA MB (Study III) 
The DTPA-isothiocyanate (0.2 mg DTPA/108 MB) was added to a suspension of 
AGMB (10 mM NaHCO3, pH = 8). The reaction mixture was shaken overnight, 
washed and separated by centrifugation (30 g, 40 min). Polyamines in the top layer of 
the MB surface reacted with isothiocyanate (pH = 8) to form a stable isothiourea bond 
in molecules containing DTPA, which were functionalized onto MB.   
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3.1.7 Preparation of Multiple Layer NOTA MB (Study III) 
NOTA-isothiocyanate (0.2 mg NOTA/108 MB) was added to a suspension of AGMB 
(10 mM NaHCO3, pH = 8). The reaction mixture was shaken overnight and washed 
using centrifugation. 
 
3.1.8 Preparation of Multiple Layer PMAA MB (study III) 
The AGMB were coated in a standard PMAA (MW approximately 1x105 g/mol 
solution (pH = 6.2) for 1 day. The reaction mixture was washed using centrifugation. 
 
3.1.9 Synthesis of Multiple Layer Microbubbles Containing 
Fluorescein Isothiocyanate and Coating with Super 
Paramagnetic Iron Oxide (Study III, IV) 
The multiple layer SPION MB used in this PhD thesis were synthesized and produced 
as described previously [18]. Poly(vinyl) alcohol (PVA) was dissolved in water (20 
g/L). 7.6 g of sodium periodate was then added and the mixture was incubated (85°C, 1 
h), cooled to room temperature and suspended for 3 h using an Ultra Turrax (8000 rpm, 
IKA-2000, Staufen, Germany) followed by washing three times in a cream centrifugal 
separator (RZ OPS, 3000 rpm, Merryfarm, Kiev, Ukraine). The MB were modified 
with amino guanidine (AG) to enable further coupling with different layers according 
to the following procedure: the MB (100 mL, 7.1x1010 MB) were washed in 0.1 M 
HEPES buffer (pH = 8, 200 mL), aminoguanidine (5 mg/mL) was added and the 
suspension was put on a shaker for three days followed by washing and centrifugation. 
A poly(allyl) amine hydrochloride (PAH 15,000) layer was then attached to the MB to 
undercoat the magnetite. The coating solution contained 1 g PAH/L in a 50 mM acetate 
buffer (pH = 5.6) plus 0.1 M NaCl. The aqueous magnetite coating solution was added 
to the MB (12 mL/109 MB) plus 1 M acetate buffer (pH = 5.6) to obtain a concentration 
of 50 mM. NaCl (1 M) was added drop wise until the NaCl concentration reached 0.1 
M. The sample was put on a shaker at room temperature overnight followed by the 
separation of the upper phase using centrifugation (30×g, 40 min). The subnatant was 
removed. From when the first magnetic layer had been attached to the MB, the solution 
was washed and separated in a magnetic field using a Neodymium magnet. This 
separation procedure was repeated for each layer. The MB (with the layers (Magnetic 
layer1)/PAH1/Magnetic layer 2/PAH2/Magnetic layer 3/PAH3) were coated by (2 x 80 
mL PSS) per 5 x 1010 MB as described above. The negatively charged MB were 
washed and coated by 100 mL fluorescein isothiocyanate (FITC)-labeled PAH 15,000 
(PAH-Flu) (1 g/L polyelectrolyte, 50 mM acetate buffer (pH = 5.6) and 200 mM NaCl, 
followed by an additional 100 mL PSS for coating and washing. A poly (allyl) amine 
hydrochloride (PAH) layer was attached to the MB to undercoat the iron oxide. PAH 
contains amine NH2 groups that can react with Fluorescein isothiocyanate (FITC) to be 
labeled (pH = 8) overnight. The product was purified using dialysis. The negatively 
charged MB with PSS as outmost layer were then coated by the fluorescein labeled, 
positively charged PAH. Thereafter, the MB were again coated with PSS to provide a 
negatively charged surface.  
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Figure 7. Showing the shell of a multiple layer MB consisting of a gas core, PVA shell, 
aminoguanidine (AG), Poly(styrene)sulfonate (PSS), Poly(ethylene) imine (PEI), 
Polyallylamine (PAH) with SPION between the PAH layers. By G. Egri, Surflay Nanotec 
GmbH, Germany. 
 
3.1.10 Preparation of Multiple Layer Magnetic Microbubbles with 
NOTA (NOTA-SPION MB) or DTPA (DTPA-SPION MB) (Study 
III) 
The AGMB were coated by layers of poly(styrene) sulfonate (PSS), poly(ethylene) 
imine (PEI) and poly (allyl) amine (PAH) as PSS 70,000/PEI 25,000/PSS 
/PEI/PSS/PAH. To this base, magnetite/PAH/magnetite/PAH/magnetite/PAH was 
attached using the Layer by Layer (LbL) technique [86]. When the first magnetic layer 
had been attached to the MB, they were washed and separated in a magnetic field. This 
procedure was repeated for each layer. The NOTA or the DTPA ligand was then 
coupled covalently to the outmost PAH-layer as described in section 3.1.5 and 3.1.6. 
The incorporation of SPION in MB was determined to 3.8 mg Fe/109 MB/mL.  
3.1.11 99mTc-MB Synthesis (Study III) 
Reduced 99mTc is chemically reactive and can react with a chelating agent to become a 
99mTc-chelate. The chemical group –COO- is the electron donor of DTPA and NOTA 
and NH2 is the electron donor of chitosan as follows:  
 
299mTcO4- + 16H+ + 3 Sn2  299mTc4+ + 3Sn4+ + 8H2O 
 
Reduced 99mTc + chelating agent  99mTc-chelate 
 
Sodium pertechnetate (99mTc-NaTcO4) was obtained from a 99Mo/99mTc-generator. 
99mTc was obtained using the reducing agent stannous chloride SnCl2·2H2O (Sigma-
Aldrich, Germany). Plain-, chitosan-, DTPA-, NOTA-, PMAA-, DTPA-SPION- or 
NOTA-SPION MB (0.2 mL of 108 MB/mL) were diluted with 0.3 mL isotonic saline in 
2 mL Eppendorf tubes. A half mL SnCl2·2H2O was added to the MB solution at room 
temperature. 99mTc-NaTcO4 (0.5 mL) with an activity of 1000-1500 MBq (Dose 
Calibrator CRC®-15 PET, CAPINTEC INC. Pittsburgh, USA) was added to the ligand 
functionalized MB-SnCl2 solution for the reduction reaction (5 min,  pH = 5). The 
Eppendorf tubes were centrifuged (500 rpm, 4 min, Hettich Universal 16, Germany) 
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and the subnatants were removed. After centrifugation, isotonic saline was added and 
the procedure was repeated until the radioactivity in the subnatant was equal to or less 
than 5 % of the activity of MB in the upper phase of MB. To evaluate the stability of 
labeled MB, 0.2 mL (109 MB/mL) of DTPA functionalized MB and plain MB were 
labeled as above using 60 MBq. The MB were washed until less than 5 % remained in 
the subnatant. MB were resuspended in saline and followed during four half-lives of 
99mTc. 
 
3.1.12 Synthesis of Multiple Layer Alexa-680 Microbubbles (Study V)                    
The Alexa-680 MB were produced as described previously [18, 84, 86]. Poly (vinyl) 
alcohol (PVA) was added to de-ionized water and dissolved followed by Ultra Turrax 
T-25 mixing (8000 rpm, IKA-2000, Staufen, Germany) for 2 h. The aminoguanidine-
MB (12 x 109 MB) aqueous solution was washed by centrifugation (60 g, 30 min) and 
the supernatant was removed. In order to enable optical imaging, the MB were 
fluorescence labeled by adding negatively charged Alexa-680 Vivo Tag (5 mg, Perkin-
Elmer, USA) poly (allyl) amine hydrochloride (PAH) onto amino guanidine. NaHCO3 
(5 mL 50 mM) was added. The solution was stirred overnight and washed 3 times in 
the centrifuge followed by the addition of negatively charged poly(styrene) sulfonate 
(PSS) coating under standard coating conditions (2 g/L polymer in 50 mM acetate 
buffer and 0.2 M NaCl, 3 mL/109 MB). This was followed by washing using 
centrifugation.  
 
3.2 ANIMAL STUDIES (STUDY I, II, III, IV, V) 
The studies were carried out at Karolinska Institutet, approved by the Stockholm 
Southern Ethical Committee on Animal Research and performed in accordance with 
Swedish Animal Welfare law.  
Male Sprague Dawley rats (study I-IV) weighing 300 g  50 g were purchased from 
Charles River (Charles River Laboratories, Germany). The animals had access to food 
and water ad libitum and 12 h light/dark cycle with controlled humidity (55% ± 5%) 
and temperature (21oC ± 2oC). The rats were anaesthetized using an intra-peritoneal 
injection of pentobarbital (sodium pentobarbital; 60 mg/mL, APL Kungens Kurva, 
Sweden) at a dose of 50 mg/kg. MR- and SPECT/CT imaging was performed on 
anesthetized, free breathing rats. The mice in study V were anesthetized using 
Isoflurane (Baxter Medical AB, Kista, Sweden) and placed prone, head first inside the 
IVIS system (PerkinElmer, Waltham, MA, USA). 
 
3.2.1 Magnetic Resonance Imaging (Study I, II, III, IV) 
The rats used for MR imaging were placed prone and “head in” in an extremity coil in 
the MR scanner (Siemens Trio, Siemens Medical Solutions, Erlangen, Germany) for 
imaging. They were imaged before and after an intravenous injection of ligand 
functionalized-, 99mTc labeled-, SPION MB or free SPION via the tail vein.  
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3.2.2 Nuclear Medicine (Study III) 
The rats examined using nuclear medicine imaging were injected with functionalized 
DTPA-, PMAA-, chitosan-, NOTA-, NOTA-SPION-, or DTPA-SPION MB and placed 
prone in a vacuum pillow between the gamma camera heads (Siemens Symbia True 
Point 16 hybrid system, Symbia® Siemens, Erlangen, Germany), enabling dynamic 
scintigraphic measurements and tomographic SPECT/CT imaging.Rats injected with 
99mTc labeled MB were sacrificed and their organs removed post mortem for 
radioactivity measurements using a Dose Calibrator (CRC®-15 PET, CAPINTEC INC. 
Pittsburgh, USA). 
 
3.2.3 Histology (Study II, IV) 
The rats that were examined histologically were injected with an intra-peritoneal (i.p.) 
injection of 60 mg/kg sodium pentobarbital and fixed onto a surgical pad in supine 
position. A surgical incision along the chest midline was made and the skin, the anterior 
part of the peritoneum and the diaphragm were cut. The right atrium was incised to 
release intravascular pressure and 40 mL of heparinized PBS and 60 mL of ice-cold 
fixation solution (paraformaldehyde (PFA), 4 %, Solveco, Sweden) were injected very 
slowly through a needle inserted in the left ventricle. The perfusion of the corporal 
circulation was monitored by observing the liver turning pale. Tissues were then 
dissected and transferred to 4 % PFA. After 48 h the PFA was replaced by 70 % 
ethanol before further dehydration and paraffinization of selected tissue samples in a 
vacuum infiltration processor. The organs were embedded in paraffin according to 
RENI trimming guidelines [87-89]. The blocks were sliced, mounted for examination 
under the microscope.  
 
3.2.4 In Vivo Imaging System (Study V) 
FVB/N mice were purchased from Charles River (Charles River Laboratories, Sulzfeld, 
Germany) and had free access to food and water, 12 h light/dark cycle, controlled 
humidity (55 %  ±  5 %) and temperature (21°C ± 2°C). The mice were injected 
intravenously with MB into their lateral tail vein, while awake in a mouse strangler. 
Prior to image acquisition, the mice were anaesthetized using 2-3 % Isoflurane (Baxter 
Medical AB, Kista, Sweden). Isoflurane (1-2 %) was used for anesthesia maintenance. 
The anesthetized mice were placed dorsal side up in a Mouse Imaging Shuttle (MIS) 
and imaged using IVIS 2D, -3D tomography at 30 min, 2 h, 4 h and 24 h post-injection 
followed by Quantum FX-µCT (PerkinElmer, Waltham, MA, USA) and Visual Sonic 
ultrasound (Vevo 2100 (FUJIFILM VisualSonics Inc., Toronto, Canada).  
 
3.3 MEDICAL IMAGING 
 
3.3.1 Magnetic Resonance Imaging Protocol (Study I, II, III, IV) 
The MR examinations in this thesis were performed using a commercially available 3 T 
MR system (Siemens Trio, Siemens Medical Solutions, Erlangen, Germany) [18, 85, 
90]. An extremity coil was used for imaging. A home-made T2 star (T2*) sequence 
developed for measuring iron oxide content was used with 12 echo times (TE) and 1.9 
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ms increments. The contrast agent was injected intravenously into the tail vein of 
anaesthetized rats. Imaging was performed using a gradient echo T2* sequence to 
obtain images with a fixed repetition time of 2000 ms and 12 stepwise increasing echo 
times (TEs) of 2-22.9 ms. Field of view read was 250 mm with a phase encoding of 
59.4 % and a slice thickness of 3 mm. Circular ROIs were placed manually in the 
respective organs on areas with a small standard deviation of <100 mm. The negative 
logarithmic values of the signal intensities at different TEs were plotted versus the 
respective TEs followed by the calculation of T2*. In organs with short T2*, the 
calculations of T2* were based on fewer measurement points, excluding those with 
long TEs where full transaxial relaxation had already occurred [18]. 
 
3.3.1.1 Study 1 
Phantoms and animals were scanned using 3 T MRI pre- and post-injection of 0.5 mL 
of   4.7 × 108 single layer SPION MB/mL through the tail vein. 
 
3.3.1.2 Study 2 
MR Phantom Study: 
The SPION MB solution was analyzed using inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) (Thermo Scientific iCAP 6500, Thermo Fisher 
Scientific, Waltham, MA, USA) to determine the concentration of iron oxide (Fe3O4). 
Three phantoms containing SPION MB were produced by agarose (Sigma-Aldrich 
Sweden AB, Stockholm, Sweden), which was mixed into water to obtain a 
concentration of 3 w %, then heated to 85°C. The hot, liquid agarose gel was poured 
into Falcon tubes (Thermo Fisher Scientific Inc., Waltham, MA, USA) and mixed with 
SPION MB to obtain three concentrations of Fe3O4 (0.125, 0.25 and 0.5 mM) followed 
by cooling to RT. The SPION MB agarose phantoms were imaged at 3 T (Siemens 
Trio, Erlangen, Germany) using the extremity coil and a T2* sequence with 12 
increasing echo times of 2 ms to 22.9 ms [85]. Regions of interest (ROIs) were drawn 
on the phantom MR images and the signal intensity was measured in each ROI. This 
was followed by the calculation of the spin-spin relaxation rate (R2*) for each 
phantom. R2* was plotted against its Fe3O4 concentration, to obtain a standard curve.  
 
MR Animal Study: 
The animals were injected with 0.75 mL of 1x109/mL single layer SPION and scanned 
dynamically at 3 T MRI. The MR scans were repeated pre injection and post-injection 
until 2 h and then at 24 h, 48 h, 72 h, 1 w, 2 w, 3 w and 4 w. 
 
3.3.1.3 Study 3 
The rats were injected intravenously with 0.5 mL during dynamic scintigraphic 
measurement and imaged prone using fusion SPECT/CT. The animals injected with 
MB containing SPION were brought to the MR scanner for co-registration to enable 
fusion SPECT/MR imaging. Each of the animals injected with SPION MB was 
examined 1-2 times using MRI.  
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3.3.1.4 Study 4 
 Several (up to 10) MRI examinations at 3 T using T2* were performed at different 
occasions on each animal to enable pharmacokinetic calculations after the injection of 
fluorescent FITC-SPION MB (0.5 mL, 1x109 MB/mL) i.v into the tail vein of the rats. 
The animals were free breathing and anesthetized using an intra-peritoneal injection of 
Pentobarbital. The animals were taken back to their cages between MR scans and 
allowed to rest for at least 24 h before the next imaging session.  
 
3.3.2 Nuclear Medicine Imaging: Dynamic planar Scintigraphy and 
Single-Photon Emission Computed Tomography / Computed 
Tomography Protocols (Study III) 
 
SPECT/CT imaging was performed using a Siemens Symbia True Point 16 hybrid 
system (Symbia® Siemens, Erlangen, Germany) with parallel hole LEHR collimators 
[18]. The dynamic planar scintigraphy (2 frames per second) was carried out with a 
total duration of 11.4-11.7 minutes. The matrix size was 256 x 256 with a 15 % wide 
energy window for 99mTc and the SPECT matrix size was 128 x 128. SPECT was 
performed with 64 projections over 360°, non-circular, step and shoot mode. The 
duration of each projection was 60 seconds. The total acquisition time required for 
SPECT was 32 minutes. Immediately after the SPECT acquisition, a CT scan was 
performed with a tube current of 110 kV, quality ref mAs was 160 mAs modulated 
with CareDose4D®, rotation time of 0.6 seconds and pitch 1.0. The CT data was 
reconstructed with a slice thickness of 0.75 mm and a “B70s sharp” kernel. A 3D 
Gaussian post filter (0.8 cm FWHM) was finally applied. Regions of interest (ROIs) 
were outlined for the organs on the dynamic images and counts were measured in each 
ROI using the Hermes system. No correction for radioactivity decay was made due to 
the short time interval. The number of counts in each organ was compared to the total 
counts in the whole animal to obtain the percentage of distribution to each organ. 
Interpretation of fused SPECT/CT images was made in three orthogonal planes. 
Reconstruction of the SPECT data and evaluation of the resulting images as well as 
fusion of SPECT/CT and SPECT/MR images were made on a Hermes workstation 
(Hermes Medical Solutions AB, Stockholm, Sweden). For SPECT/MR fusion the MR 
images were imported from the Picture Archiving and Communication System (PACS) 
to the Hermes system and then overlaid with the respective SPECT image to obtain 
fusion SPECT/MRI, which shows both anatomy and function in the same image. 
Iterative reconstruction was made with ordered subset expectation maximization 
(OSEM 4 iterations, 8 subsets, including resolution recovery). A phantom was made 
using agarose with three parallel vessel sized holes transversal through the phantom. 
For imaging the respective holes were injected with 99mTc labeled chitosan MB.  
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3.3.3 Ultrasound Protocol (Study I, V) 
In order to preliminarily evaluate the MB distribution in specific organs, ultrasound 
imaging was performed in mouse liver, kidney and spleen tissue before injection and in 
mouse liver, kidney and spleen tissue 24 h post-injection using a high frequency 
ultrasound system, Vevo 2100 (FUJIFILM VisualSonics Inc., Canada). Ultrasound 
images were obtained both in b-mode (liver imaging: f = 18 MHz, frame rate = 18/s; 
kidney and spleen imaging: f = 21 MHz, frame rate 10/s) and in non-linear contrast 
mode (f = 18 MHz, frame rate = 18/s). Prior to image acquisition, the mice were 
anesthetized utilizing 3-4 % Isoflurane (Baxter Medical AB, Kista, Sweden), and 
anesthesia was maintined using Isoflurane (1-2 %, Baxter Medical AB, Kista, Sweden). 
During anesthesia, the body temperature was controlled by a heating pad. In addition, 
heart rate and respiratory frequency were monitored.  
 
3.3.4 In Vivo Imaging System Protocol (Study V) 
Imaging was performed using IVIS spectrum 2D and Quantum FX (PerkinElmer, 
Waltham, MA, USA). Fluorescent images were taken using the following 
Excitation/Emission filter pairs: 640/680nm, 675/720nm, 675/740nm, 675/760nm and 
675/780nm.  The spectral un-mixed 2D image (fluorescence photograph) was acquired 
with epi-illumination as a reference to verify the location of uptake and to select trans-
illumination locations. The mice were imaged using a 3D FLIT imaging sequence that 
was acquired at excitation 675 nm and emission 720 nm. After in vivo imaging of 
Alexa-680 MB distribution, the organs (lungs, liver, spleen, kidneys) were removed 
and imaged separately post mortem with 2D epi-illumination fluorescence imaging, 
using a filter pair of 675/720nm. 3D FLIT image reconstruction, spectral un-mixing for 
auto fluorescence background removal, FLIT-CT co-registration and fluorescence 
efficiency quantification were generated using Living Image® 4.2 software 
(PerkinElmer, Waltham, MA, USA). 
 
IVIS imaging was performed using both 2D and 3D tomography in vivo as well as 2D 
ex vivo on the organs post mortem. The mice were anesthetized using Isoflurane 
(Baxter Medical AB, Kista, Sweden) and placed prone, head first inside the IVIS 
system. The option for imaging fluorescent nanoparticles using the epi-illumination 
mode was chosen, and was followed by spectral un-mixing. The excitation filters 
chosen ranged between 500-780 nm and the emission filters chosen ranged between 
640-780 nm. Initially, a 2D image (fluorescent photograph) was acquired with epi-
illumination to verify the location of uptake. Thereafter, the mice were imaged using 
the 3D mode surface tomography (FLIT) with trans-illumination. The CT images were 
co-registered to show the anatomical map of the mice.   
 
3.3.5 Small Animal Computed Tomography (Study V)  
The mice were scanned and co-registered using computed tomography (CT). The 
mouse was placed prone in the co-registration shuttle MIS, sequentially imaged and 
subjected to a CT scan with a field of view at 75 mm, with three minutes X-ray 
exposure (Varian Medical Systems, Salt Lake City, UT, USA).  
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3.4 PHARMACOKINETIC MODELING  
 
After MR measurement of R2* in rat liver the baseline value was subtracted, and the 
corresponding iron oxide concentration for each R2* value was read from the standard 
curve. The concentration data in the rat liver was fitted to a one-compartment open 
model[18]. Parameters such as elimination rate constant, maximum concentration 
(Cmax) and micro constants were estimated. The area of the concentrations versus time 
(AUC) was calculated from the model-derived parameters and the elimination half-life 
was calculated from the slope of the terminal phase of elimination. Pharmacokinetic 
modeling was performed using WinNonLin version 5.0 (Pharsight, Mountain View, 
CA, USA). The mean, median and standard deviation (SD) of all parameters were 
calculated using GraphPad (version 4.0, Graph Pad, San Diego, CA, USA). All values 
are presented as mean ± SD.  
 
3.5 HISTOPATHOLOGY (STUDY II, IV, V) 
 
3.5.1 Perls’ Prussian Blue Staining and Quantification  
For histological quantification of MB in tissues, Perls’ Prussian blue stained slides were 
digitally scanned using a 3D HISTECH Panoramic slide scanner (3DHISTECH, 
Budapest, Hungary). Repeated measurements of a minimum area of 1 mm2 was 
selected for lungs, liver and spleen (n = 5) from each animal for digital counting of MB 
based on their iron content, using Nikon Elements BR-software (Nikon Instruments 
Inc., Melville, NY, USA).  
3.5.2 Immunohistochemistry  
To confirm the phagocytosis of MB by macrophages in organ tissue from liver, spleen 
and lungs, immunohistochemistry was performed with a primary antibody against 
CD68 macrophage marker (MCA 341, AbD Serotec, Kidlington, Great Britain). The 
secondary antibody was alkaline phosphatase conjugated rabbit anti-mouse (Sigma 
A4312, Sigma, St. Louis, MO, USA). The Vector red substrate (Vector, SK5100, 
Vector Laboratories Inc., Burlingame, CA, USA) produced a red signal for bright field 
as well as red fluorescent microscopy. The slides were cover slipped utilizing DAPI 
containing mounting medium (Vector VECTASHIELD® H1200, Vector Laboratories 
Inc) to produce nuclear counter stain and the slides were further evaluated using a 
confocal microscope with appropriate fluorescence filters for FITC, Cy5 and DAPI 
(Nikon A1R, Tokyo, Japan).  
 
3.6 THERANOSTICS AND DRUG DELIVERY  
 
3.6.1 Busulfan Labeled Microbubbles 
The cytostatic Busulfan (Bu) was dissolved in dimethyl sulfoxide (DMSO) (50 µl) and 
mixed with 50 µl 108 pre-formed MB/mL. The Bu-MB sample was incubated at room 
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temperature on a wheel rotator for 72 h. DMSO was taken up by MB, which were 
transformed into microcapsules (MCs). The MCs were dialyzed and the dialysate was 
replaced at 2, 4, 6 and 24 h. The microcapsules were harvested, washed, re-suspended 
in acetonitrile and analyzed using gas chromatography (GC) with an electron capture 
detector.  
 
In another experiment, the microcapsule pellet containing Bu was resuspended in 200 
µl isotonic saline. Tin chloride (SnCl2) and sodium pertechnetate (69.7 MBq) were 
added to the MCs and reduction was allowed to take place for 5 minutes. The sample 
was washed with isotonic saline and centrifuged at 500 rpm for 4 minutes. Activity was 
measured to be 0.74 MBq in the supernatant and 10.8 MBq in MCs (93 % pure). 0.5 
mL of 99mTc labeled busulfan MCs (2.5 MBq) was thereafter injected i.v. into the tail 
vein of a Sprague Dawley rat. Dynamic gamma camera measurement was carried out 
for 684 seconds followed by SPECT/CT (Siemens Symbia) using 64 projections, 60 
seconds/angle.  
 
3.6.2 99mTc Labeled Dexamethasone-DOTA-SPION Microbubbles for 
the Treatment of Muscle Inflammation in Rat 
 
The content of one Eppendorf tube of freeze-dried Dexamethasone-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-SPION MB (dexamethasone 
21-acetate (DMA) from lyophilized MBspH5RT/b-cyclodextrins) was dissolved in 1 
mL saline and labeled with 99mTc. A start activity of 291 MBq/mL of Tc-pertechnetate 
was added in addition to the MB. A Sprague Dawley (480 g) rat was sedated using 
Isoflurane and anesthetized using an intra-peritoneal (i.p.) injection of 0.35 mL 
Pentobarbital (60 mg/mL, APL, Kungens Kurva, Sweden). The hair was removed on 
both hind legs using hair removal cream (Veet). A wireless Bluetooth gamma probe 
(neoprobe® GDS Gamma detection system) was utilized to measure the local number 
of counts in the organs of the rat by placing the gamma probe vertically towards/on the 
skin over the target organ. A circular 7 mm Neodymium Iron Boron NiCuNi coated 
2500 Gauss magnet (Panduro, Sweden) was attached with tape onto the skin of the 
right hind leg calf muscle followed by an intravenous (i.v) bolus injection of 99mTc 
labeled MB (60 MBq, 1 mL).  
 
The magnet was removed and the rat was placed prone, head first, under the gamma 
camera (Siemens Symbia True Point 16 hybrid system (Symbia®, Siemens, Erlangen, 
Germany) and scanned using dynamic planar scintigraphy (2 s, 150 frames) for 300 s. 
The matrix size used was 256 × 256 and a suitable energy window for 99mTc was used, 
15 % wide. Immediately after the dynamic imaging, a SPECT tomography was run 
using a 128 × 128 matrix, 64 projections over 360° of 60 sec/projection, non-circular 
orbit, step-and-shoot mode. The acquisition time required for SPECT was 32 min. The 
CT scan was performed with a tube current of 110 kV, quality reference was 160 
milliampere sec (mAs), modulated with CareDose4DW; rotation time was 0.6 sec, and 
the pitch was 1.0. Subsequently, the CT data was reconstructed with a slice thickness of 
0.75 mm and a “B70s sharp” kernel. Reconstruction of the SPECT/CT images was 
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done on a Hermes workstation (Hermes Medical Solutions AB, Stockholm, Sweden). 
The iterative reconstruction was done with ordered subset expectation maximization 
(four iterations, eight subsets, including resolution recovery). A 3D Gaussian post filter 
(0.8 cm FWHM) was finally applied. After 14 h the rat was re-scanned using dynamic 
imaging and SPECT/CT.  
 
The rat was scanned pre- and post-injection (2 h post-injection and 24 h post-injection) 
using a 3 T MR scanner (Siemens Trio, Siemens, Erlangen, Germany). The rat was 
placed head first, prone, in an extremity coil. Imaging was performed using a gradient 
echo T2*sequence to obtain images with a fixed repetition time of 2000 ms and 12 
stepwise increasing echo times (TEs) of 2 to 22.9 ms. Field of view was 250 mm with a 
phase encoding of 59.4 % and a slice thickness of 3 mm. Circular ROIs were placed in 
the respective organs, and the negative logarithmic values of signal intensities at 
different TEs were plotted versus respective TE values followed by calculation of T2*.  
Coronal and transversal T2 Turbo Inversion Recovery Magnitude (TIRM) sequences 
were run with fixed TE of 80 ms, fixed TR of 5000 ms and flip angle 120. The 
sequence is sensitive to denervated or inflamed muscle preceding muscle atrophy. T2 
HASTE coronal was applied with TE = 91 ms, TR = 2000 ms and flip angle = 150. 
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4 RESULTS 
 
4.1 MICROBUBBLE SYNTHESIS 
Plain MB, single layer SPION-, chitosan MB, multiple layer DTPA-, NOTA-, PMAA-, 
SPION-, DTPA-SPION-, NOTA-SPION-, 99mTc-labeled FITC-SPION-, Alexa-680 
MB as contrast media for imaging were manufactured as described above. The MB 
were not shown to aggregate in water solution, nor did they contain any debris seen by 
visual inspection in the light microscope (Figure 8A and B). Figure 8A shows the  
SPION MB labeled by fluorescent FITC. High resolution TEM reveals that the SPION 
MB particles have an average diameter of ca. 3.1 μm (Figure 8C). The single crystal 
structure of SPION, embedded in between the shell layers of SPION MB, were 
measured to have an average size of 12.4 nm (Figure 6D). Moreover using forward 
scattering (FSC) flow cytometry shows the size distribution to be around 80 as a mean 
showing that SPION MB were not aggregated nor contained debris; while using 
sideward scattering (SSC) gave us information about the surface.   
 
Figure 8. SPION MB visualized in the light microscope (image size 550 µm x 550 µm, Leica 
TCS SPE) using the FITC channel (A) and in bright-field microscopy setting (B). Two 
microbubbles (MBs) seen in the electron microscope (C) and crystal lattice parameters of 
SPION (D) using JEOL JEM-2100F field emission transmission electron microscopy (FE-
TEM), Barrefelt et. al., International Journal of Nanomedicine 2013:8(1) pages 3241 – 3254. 
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4.2 MAGNETIC RESONANCE IMAGING 
 
Agarose phantoms were mixed with SPION MB. Figure 7 shows two phantoms imaged 
at TE = 2 (A), 3.9 (B) and 5.8 ms (C). The phantom in the top row contains agarose gel 
while the phantom in the lower row contains SPION MB at a concentration of 0.5 mM. 
The MR signal intensity in the phantom containing SPION MB decreases with 
increasing TE (bottom row); while the signal in the phantom with only agarose gel 
stays rather constant. The signal decrease in the phantoms containing SPION MB  
enables the calculation of T2* and R2* for the calculation of a standard curve. The iron 
oxide (Fe3O4) concentration of the SPION MBs was calculated to be 4.73 mM (265 
ppm) as measured using ICP-AES. The standard curve (R2* versus [Fe3O4]) was 
calculated from R2*.  
 
Sprague Dawley rats were injected i.v. with either single- or multiple layer SPION MB, 
2 h after which the T2* value of the liver had decreased to its minimum (Figure 8). 
After injection of SPION, the liver T2* reached its minimum in less than 1 h. The 
elimination half-life of SPION MB was 598.2 ± 97.3 h for single walled PVA MB, 
while for multiple walled SPION MB the half-life was 741 ± 219 h and for free SPION 
222.6 ± 26.4 h. Using histopathology, by Perls’ Prussian blue staining and 
immunohistochemistry we showed that single layer SPION MB, SPION and plain MB 
were accumulated in the liver through macrophage uptake and were then slowly 
eliminated.  
 
Multiple layer fluorescent FITC-SPION MB were injected into rats to determine their 
biodistribution, biological fate and kinetics using MR imaging and histopathology. By 
staining CD68+, histopathology could show the uptake of the FITC-SPION MB by 
macrophage uptake in the liver and spleen. Histological findings were correlated with 
MR imaging since we could detect iron uptake by Perls’ Prussian staining and for the 
same time points also detect signal decrease on T2* weighted images.  
 
The rats injected with multiple layer, ligand functionalized, 99mTc-labeled DTPA 
SPION MB were co-registered using hybrid SPECT/CT and MR imaging. By fusion of 
the images we could detect uptake of DTPA-SPION MB primarily in the lungs at 1 h 
post-injection while the MB could be seen in the liver at 1 h and 24 h post-injection. 
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     A.                            B.                              C. 
 
   D.                       E. 
Figure 9. Agarose phantoms containing SPION MB imaged at 3 T MRI. The signal intensity is 
relatively constant in the agarose phantom without iron oxide (uppe row), but decreases with 
increasing echo time, TE = 2 (A), 3.9 (B) and 5.8 (C) ms, in a phantom containing SPION MB. 
Phantoms of increasing SPION concentration (C =  0, 0.01, 0.02, 0.03, 0.04, 0.05, 1 and 2 mM) 
were imaged at TE = 3.9 (D) and 5.8 (E) ms. This shows that by increasing TE values, the 
signal intensity and T2* decrease; hence this leads to an increase in R2*. 
 
 
Figure 10. The negative logarithmic values of the signal intensities at different TEs are plotted 
versus the respective TE value (ms). The spin-spin relaxation time, T2 star (T2*), could then be 
calculated as the slope of the semi-log plot of the signal intensity versus the echo times (TEs). 
This image shows that due to fast decay only the first TE values (TE = 2-11.5 ms) can be used 
for calculating slope of the curve. If all TEs would be used for the calculation, this would lead 
to underestimation of the slope, as can be seen from the straight line going through TE = 2-22.9 
ms.  
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Figure 11. T2 weighted 3 T MR image (Siemens Trio, Siemens, Erlangen, Germany) showing 
one rat imaged using the T2* sequence. The left image shows the rat pre-injection, while the 
right image shows the rat post-injection. Signal decrease on the T2* weighted images can be 
visualized in the liver of the rat, which shows that SPION MB are uptaken primarily in the 
liver. This was confirmed by R2* calculations; which shows that R2* increase in the liver post-
injection.    
 
 
Figure 12. The 3 T MR image shows the same rat imaged using three echo times, TE = 2, TE = 
3.9 and TE = 5.8 ms. The images in the upper row shows a non-injected rat; while the images in 
the lower row shows the same rat injected with SPION MB. One can see that as the TE value 
increases, the signal intensity in the liver tissue decrease (left to right). 
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4.3 NUCLEAR MEDICINE IMAGING 
 
Fusion SPECT/CT and MRI showed that the biodistribution of 99mTc-labeled ligand 
functionalized MB varied with the type of ligand. One h post-injection of 99mTc-labeled 
DTPA- and chitosan MB, the highest uptake was observed in the lungs, while PMAA 
MB were evenly distributed between the lungs and the liver. The highest counts of 
99mTc labeled NOTA-SPION and DTPA-SPION MB were observed in the lungs, liver 
and kidneys 1 h post-injection, while the highest counts were observed in the liver, 
spleen and kidneys at 24 h post-injection as confirmed by MRI. MR shows a signal 
decrease in the liver but, due to the uptake of 99mTc labeled MB in the liver, there is 
overlap and the signal decrease cannot be detected. However, the MR image provides 
an anatomical map of the rat. Fusion SPECT/CT enables us to see the anatomical 
structures of the rat.  
 
 
A. 
 
B. 
Figure 13. An agarose phantom imaged using SPECT/CT. (A) is sagittal view, while (B) 
shows the phantom in the coronal view. 99mTc labeled MB were injected into the middle, rat 
sized aorta. The middle aorta is isodense on the CT image (B). The SPECT image (B) is more 
blurred, which shows that the resolution is less in SPECT than in CT. 
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Figure 14. A rat imaged prone using SPECT/CT (A) and 3 T MR (B) 1 h post-injection of 
NOTA-SPION MB. The image shows primary uptake of MB in the lungs and liver on the 
SPECT image while the MR image cannot show uptake in the lungs due to air, but signal 
decrease is detected in the liver (B). After 24 h the MB have redistributed to the liver and spleen 
(C). The findings from imaging were confirmed by measuring radioactivity in organs post 
mortem. At 24 h post-injection using 3 T MRI we can detect signal decrease (MB) in the liver 
with decreased intensity compared to 1 h post-injection. Published by Barrefelt et. al. in 
EJNMMI Research 2013, 3(1):12. 
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A.                                          B. 
Figure 15.  The rat from Figure 14 is imaged using SPECT/CT in the transversal plane. At (A), 
1 h post-injection, MB are found in the lungs, while at (B), 24 h post-injection, MB are 
visualized in the liver. 
 
 
Figure 16. Dynamic scintigraphic image showing the biodistribution of DTPA-SPION MB as 
measured in ROIs on dynamic images at 1 h (A) and 24 h (B) post-i.v. injection.  
 
4.4 IN VIVO IMAGING SYSTEM 
 
MB were mainly distributed to the lungs as seen using IVIS 2D and 3D. At 30 min, 2 h 
and 4 h post-injection, the fluorescence signal was mainly seen in the lungs and liver, 
while at 24 h the signal had re-distributed to be seen mainly in the liver. The results 
obtained from in vivo 3D FLIT images were in agreement with those obtained from ex 
vivo 2D fluorescence images of uptake in the organs.  
 
4.5 PHARMACOKINETIC MODELING 
 
MR imaging could be used for calculating and presenting the elimination of SPION 
MB using a pharmacokinetic model by WinNonLin version 5.0 (Pharsight, Mountain 
View, CA, USA). The concentration of single layer SPION MB in the liver at the 
different time points was calculated and represented as µg/mL versus time (h). The 
maximum concentration (Cmax) was calculated to be reached after 1.2 h, after which the 
concentration decreased. The half-life (T1/2) was 598.2 ± 97.3 h for SPION MB. T1/2 of 
SPION MB in rat liver was 598.2 ± 97.3 h, while SPION had a half-life in liver of 
222.6 ± 26.4 h. Clearance (CL) was 0.011 ± 0.003 mL/h for SPION MB, while for 
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SPION it was 0.026 ± 0.0027. Tmax for SPION MB was calculated to be 1.17 ± 0.52 h, 
while Tmax for SPION was 0.44 ± 0.15 h. The maximum concentration Cmax was 
calculated to be 94.0 ± 13.6 µg for SPION MB, while SPION had a Cmax of 102.2 ± 2.3 
µg. R2* values in other organs such as brain, kidneys and muscle are not shown since 
calculations of T2* in these organs showed no signal decrease compared to pre-
injection.  
 
4.6 THERANOSTICS AND DRUG DELIVERY 
 
4.6.1 Busulfan Labeled Microbubbles  
Busulfan was successfully incorporated into MC with a yield of 20 % of the initial drug 
concentration. Imaging of injected busulfan MC labeled with 99mTc using SPECT-CT 
showed that busulfan MCs are distributed mainly to the liver and spleen of the rat.  
 
4.6.2 99mTc Labeled Dexamethasone-DOTA-SPION Microbubbles for 
the Treatment of Muscle Inflammation in Rat 
 
The T2 TIRM MR sequence can image muscle inflammation. A high signal area was 
visualized at the place of the injection. This could show the muscle being inflamed due 
to liquefaction around the inflammation; alternatively, the high signal area of the rat leg 
might also be caused by remains of the injected lipopolysaccharides (LPS) in liquid 
form, since fluids produce a bright signal on T2 TIRM images.  
 
 
Figure 17. A rat imaged at 3 T MRI (Siemens Trio, Siemens, Erlangen, Germany) using T2 
Turbo Inversion Recovery Magnitude (TIRM) in the coronal plane (A) and in the transversal 
plane (B) after the intra muscular injection of LPS. TE = 80 ms, TR = 5000 ms and flip angle 
120. 
 
99mTc Labeled Dexamethasone-DOTA-SPION MB were injected and the radioactivity 
was measured immediately post-injection by using a Gamma probe. The number of 
counts measured using the Gamma probe on the legs and respective organs were as 
follows: in the right hind leg 5000, left hind leg 3000, liver 60 000, lungs 50 000 and 
intestines 40 000 counts.  
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Figure 18. A rat injected with 99mTc labeled Dexamethasone-DOTA-SPION MB and imaged 
using fusion SPECT/CT (Siemens T-16). The MB were mainly distributed to the lungs and the 
liver at 1 h post-injection. 
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5 DISCUSSION 
 
In this thesis we have shown that ligand functionalized DTPA-, NOTA-, chitosan-, 
PMAA-, DTPA-SPION-, NOTA-SPION and Dexamethasone-DOTA-SPION MB can 
be labeled with 99mTc to enable imaging using nuclear medicine imaging techniques. 
Different ligands affected the yield of labeling of MBs, however, we have also 
observed that plain MB could be labeled, which could be explained by the unspecific 
uptake or incorporation of radiomarkers by the polymer matrix. The highest labeling 
yield was observed in MB functionalized with DTPA, followed by PMAA and NOTA. 
The distribution of MB in Sprague Dawley rats was studied using dynamic planar 
scintigraphy (2D) and SPECT/CT (3D tomography). Hybrid imaging using the 
combination of SPECT and CT images was performed by fusing images to produce 
SPECT/CT imaging. SPECT is utilized to show the locations of uptake of radiomarker, 
while CT gives an anatomical map of the body which will be used for verification of 
which organs are involved. Hybrid imaging or multimodal imaging is frequently used 
in clinical practice. The use of multimodal contrast agents such as ligand functionalized 
MB is an important step towards enabling more effective use of this technique. 
Attachment of 99mTc as a ligand for further labeling gives us a dual modality contrast 
agent (US and SPECT). Moreover, if we then incorporate a CT contrast, we would 
enable trimodality use. If SPION are also attached to the MB we enable MR imaging, 
making the agent multimodal.  
 
When rats were injected with the 99mTc ligand functionalized MB intravenously 
through the tail vein, the contrast agent was mainly distributed to the lungs and to some 
extent to the liver at 1 h post-injection. After 24 h the distribution had relocated to the 
liver. Some uptake was shown in the kidney 24 h post-injection, which could probably 
be due to free 99mTc being liberated from the MB in vivo and eliminated mainly through 
the kidneys. A possible explanation could also be that the MB polymer matrix partly 
breaks into small pieces in vivo. However, histological examination shows no signs of 
broken MB in the organs. By applying an in vitro test using labeled MB resuspended in 
saline, we could detect that a non-significant amount of 99mTc had been released from 
the MB at 10 min, 30 min, 1, 3 and 24 h after 99mTc-labeling. Verification of nuclear 
medicine imaging was carried out by removing the organs and measuring their 
radioactivity post mortem. A hybrid imaging technique merging nuclear medicine 
images with MRI was examined. The rats were injected with ligand functionalized 
99mTc SPION MB and imaged first by SPECT and subsequently by 3 T MRI. By 
importing the MR image into the Hermes system, we were able to fuse the images and 
obtain a SPECT/MR image. The organ location of uptake could be distinguished 
exactly by this technique since MRI is superior in soft tissue contrast. Since the MB 
were labeled by SPION, MRI brought another dimension to the imaging result. While 
SPECT showed the uptake of MB primarily in the lungs, MRI showed uptake in the 
liver by signal decrease caused by the iron oxide. When studying the organs 
histologically we could show that as early as 2 h post-injection there was significant 
findings of MB in the liver. There was a continues decrease of the MR signal during the 
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first 24 h. To establish the distribution of  99mTc-labeled MB, a reference containing 
free 99mTc pertechnetate was injected into the rat. The distribution was mainly seen in 
the stomach, kidneys and bladder.  Some radioactivity was also observed in the thymus, 
thyroid gland and mouth mucosal membranes. The different distribution observed after 
free 99mTc pertechnetate and 99mTc labeled MB indicates that no free 99mTc was present 
in the solution when injecting 99mTc-labeled MB. Furthermore, the radioactivity in the 
respective organs was measured by drawing ROIs on the dynamic scintigraphic images 
and was found to be in agreement with visual evaluation of the SPECT/CT images. Not 
only the different ligands but the size, lipophilicity or building of polymer aggregates 
with a diameter larger than 5 micrometers could potentially cause the MB to be trapped 
in the capillary bed of the lungs. Aggregates and also large conglomerates of MB were 
unfortunately seen in the lungs in histology slides. However, after 24 h an accumulation 
of radioactivity was observed in the liver, which was shown to be MB taken up by 
macrophages using immunohistochemistry. Macrophage uptake was also visualized in 
the lungs and spleen. The disadvantage of using clinical equipment for the rats was the 
lower resolution which made it difficult to study the spleen by multimodal imaging 
techniques. However, the histology bridges the gap in imaging and verifying organ 
uptake of MB. The different imaging techniques thus give extra dimensions to the 
information on biodistribution, elimination, and physiological status that enhances the 
interpretation of data.  
 
A high labeling yield of DTPA-SPION MB and their application for multimodal 
imaging SPECT/CT/MRI could favor these MB for further studies as a theranostic 
candidate for drug delivery of cytostatics and imaging of cancers. Moreover, one could 
hypothesize that what was found in the liver was 99mTc-Tin colloids, which have 
historically been used as a radiopharmaceutical to measure and image liver function. 
However, Kyung et al. injected both pigs and rats with 99mTc-Tin colloids to follow 
their biodistribution and concluded that in small animals (rats) the 99mTc-Tin colloids 
distributed exclusively to the liver directly post-injection [91, 92]. In our study we 
observed the distribution to the lungs within the first hour, which indicates that our 
labeled MB did not contain colloids. Most of the colloids were probably removed from 
the MB through the washing steps.  
 
In the present thesis, MR imaging was furthermore used as a new method to determine 
the pharmacokinetic parameters and the biodistribution of SPION MB in the rat by 
measuring the R2* relaxivity caused by SPION MB on T2* weighted images and 
correlating R2* with iron oxide concentration using a standard curve obtained from 
phantom imaging of SPION MB. The calculated concentration of SPION MB at 
different time points could furthermore determine their elimination.  
 
Yang et al. [93] have studied another type of microbubble, PLA-PVA (poly (DL-
lactide)-polyvinyl alcohol) double-layered microbubbles with Fe3O4-inclusion. The 
authors found that the transverse relaxation rate (R2*) increases more rapidly the 
greater the volume. According to Yang, inclusion of SPION into the microbubbles 
enhances the contrast obtained both by MR and ultrasound imaging. Cai et al [94] have 
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further shown that when using the appropriate ultrasound exposure to SPION 
microbubbles aimed for MR imaging, the nanoparticles can be released to the desired 
organ of interest when the microbubbles collapse due to exposure to ultrasound.  
Weissleder et al. [95] have administered radio-labeled AMI-25 (59Fe AMI-25) at a 
dose of 40-50 μmol to the rat. The authors fitted the blood concentration data to a one-
compartment elimination model and reported the half-life in the blood to be six 
minutes, while the clearance from the liver occurred with a half-life of three days and 
from the spleen with a half-life of four days. This half-life was much shorter than the 
one in the present study; however, the authors measured half life in blood while we 
have measured it in liver tissue. 
 
Majumdar et al. [96] have described the elimination of iron containing AMI25 by a 
biphasic elimination model. Majumdar et al. calculated alpha half-life to 10 minutes 
while beta half-life was calculated to be approximately 92 minutes and about 60 % was 
taken up in the liver. These results may reflect the rapid clearance of the blood 
circulation and indicate that the iron nanoparticles were accumulated in the liver, which 
was also observed in the present investigation.   
 
Iron compounds such as AMI-25 were shown to be phagocytized by healthy liver 
Kupffer cells but not by hepatocellular carcinomas (HCCs); since they do not have 
phagocytizing capability. These results in hepatocellular carcinomas that were 
appearing bright on T2 and T2* weighted MR images while the healthy liver and 
spleen containing phagocytized SPION appeared dark [97]. In some of our rats we 
could detect white areas in the liver, indicating that those rats might have cysts or 
tumors which appear bright on the T2* weighted images. However, this should be 
further investigated. In patients with liver metastases [98], the blood clearance of AMI 
has been described by a two-compartment model with an alpha-elimination phase of 
4.4 - 22.2 minutes. The beta-elimination half-life ranged from 79 to 309 minutes. This 
short half-life may also indicate the rapid clearance from the blood and accumulation in 
the liver.  
 
Coating of SPION or SPION MB with different biocompatible polymers could change 
their half-life and facilitate their uptake. Xiao et al. have shown that the blood half-life 
was prolonged from 40 minutes to 120 minutes when zwitterionic coated SPION were 
compared with poly (acrylic) acid coated SPION, respectively [80]. However, no half-
life in liver tissue was reported. Moore et al. [99] showed that the uptake of dextran-
coated SPION was 10 fold higher in brain tumors compared to healthy brain tissue. The 
authors reported a 3-4.5 h plasma half-life of SPION in rodents, while the peak 
concentration was reached in tumor tissues 24 h post-injection. Stephen et al. [100] 
have shown that hydrophobic coating of the SPION, such as PEG or a zwitterionic 
coating, could make the SPION avoid RES uptake and thereby stay longer in the 
circulation. In our study, SPION were uncoated and therefore most probably cleared 
rapidly from the circulation and accumulated in the liver, where they were eliminated 
slowly. 
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SPION have been suggested as a targeting contrast agent for cancer imaging and 
diagnostics [81]. Since tumors have little lymphatic drainage, retained SPION in the 
tumor tissue should increase the contrast between tumor tissue containing SPION and 
healthy tissue, provided that the healthy tissue has no active uptake of SPION.  
In this thesis we have applied dynamic imaging using the T2* sequence.  
 
Briley-Saebo studied different coating materials and their effect on iron oxide particles 
in vivo and found that coating decreased the half-life of the particles [101]. The authors 
reported that the half-life of iron oxide particles in rat liver was 8 days for dextran 
coated materials, 10 days for carboxy dextran coated materials, 14 days for 
unformulated oxidized starch and 29 days for formulated oxidized starch. In the present 
studies we observed a slightly longer half-life of 31 days for multiple layer PVA 
SPION MB and 25 days for single layer MB. 
 
In our investigation, SPION and SPION PVA MB were accumulated in the liver quite 
shortly after administration as measured by using SPECT and MRI. Employing 
histopathology, we have found that SPION MB are taken up by macrophages in the 
liver and spleen [90]. SPION MB and SPION did not cause any measurable MR signal 
decrease in any other organs or tissues including the brain than liver and spleen, 
indicating that they are rapidly taken up and do not pass the blood brain barrier. 
Despite these observations we did not observe negative effects on the liver or spleen 
such as enlargement or volume reduction due to cirrhosis. This confirms the results by 
Bacon et al. [102], who injected large amounts of ferrite particles and did not observe 
any hepatotoxic effects or organelle dysfunction. They also observed a clearance from 
the body within three months. In the work of Yang et al. [93]  dual polymer PVA-lactic 
acid microbubbles containing SPION were injected into rats. A maximum signal 
decrease could be seen approximately 60 min post-injection. However, they did not 
follow the rats over time to see the return of the signal to base value. Thus no half-life 
was calculated in their study. 
 
Furthermore, we have investigated how repeated application of the 3 T magnetic field 
might affect MB wall integrity and accelerate iron loss to the tissues. Our studies did 
not show any histological indication for increased tissue iron load. The initially 
widespread intravascular clustering of SPION MB that was seen in the lungs mainly 
resolved after three weeks. An indication for possible adverse effects of intravenous 
administration of large numbers of SPION MB was found in the lungs of two rats at 
later time points, where we observed remains of organized vascular thrombi and focal 
granulomas.    
 
Theranostic experiments were carried out by loading MC with the cytostatic drug 
Busulfan. Busulfan incorporation into MC showed a good yield that should be 
sufficient for clinical use. Imaging using SPECT/CT can be utilized to visualize the 
dynamic bio-distribution of the cytostatic loaded MB and MCs in order to confirm 
uptake in the target organ. Incorporating the drug into capsules that are specifically 
accumulated in the target organ might enable dose reduction and hence decrease side 
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effects. The combination of treatment and diagnostics by imaging, theranostics, could 
be successful for the early detection of disease, imaging the progression of disease 
progression treatment effect.  
 
The theranostic experiments carried out concerning imaging and treatment of muscle 
inflammation are in an initial phase [103, 104]. Muscle inflammation caused by an 
intramuscular injection could be successfully imaged using the T2 TIRM MR 
sequence. Uptake of targeted 99mTc labeled Dexamethasone-DOTA-SPION MB could 
moreover be imaged using SPECT/CT or SPECT/MRI and uptake of 99mTc labeled MB 
in a specific, small region could be measured using a gamma probe. However since the 
distribution of the investigated MB were mainly to the lungs and liver, treatment of 
muscle inflammation was not obtained at this stage. We can speculate that by changing 
the size of MB and/or by applying a coating to MB could make them avoid RES uptake 
and thus be drawn to the magnet attached by the muscle for a potential treatment of 
inflammation.  
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6 CONCLUSIONS 
 
In conclusion, MB functionalized by different ligands can be labeled with radiotracers 
and utilized for SPECT/CT, while the incorporation of SPION in or between the MB 
shells enables imaging using MR, hence enabling combined multimodal SPECT/MR 
imaging. Our investigation revealed that the biodistribution may be modified using 
different ligands. Furthermore, using a single contrast agent with multimodal imaging, 
fusion SPECT/CT followed by MRI enables visualization of functional and anatomical 
information in one image, thus improving the diagnostic benefit to patients. Our results 
showed SPION MB to be a good contrast candidate for MR imaging. Moreover, MRI 
is a reliable and non-invasive tool that can be utilized to study the pharmacokinetics of 
SPION MB and SPION. 
 
The current studies characterized the properties of SPION MB in terms of size, size 
distribution, the effect on rat tissue in various organs in vivo, distribution, biological 
fate and relaxivity using MRI. The histological findings were in good agreement with 
the findings from MR imaging.  
 
Furthermore, we have shown that SPION PVA MB act as good contrast agent for the 
liver, which could be advantageous for diagnostics, including cancer diagnostics. We 
have also shown that sham vehicles such as plain MB without SPION give no more 
contrast compared to blank liver tissue on T2* weighted images. However, the SPION 
PVA MB were eliminated from the liver with a long half-life, which probably is not 
desirable in all clinical settings but could be advantageous for cancer imaging of the 
liver. MB have been labeled using Alexa-680 Vivo Tag, which enabled the use of in 
vivo imaging system (IVIS) and ultrasound for biodistribution studies as well as 
fluorescence microscopy for histological verification. Several studies are ongoing to 
modify SPION PVA MB in order to optimize their kinetics and use in clinical studies.    
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7 FUTURE ASPECTS 
 
Further investigations should address the dynamics of drug release from the MB, 
modifications for organ targeting, size effect on biodistribution and kinetics, tendency 
to cluster in vivo, and delivery dynamics during administration to attenuate possible 
adverse effects on the pulmonary vasculature. Future studies should address the toxicity 
of MB in vivo, and targeting of MB should be investigated to illustrate the binding to 
diseased organs. Furthermore, the loading of MB with drugs could employ them as a 
theranostic vehicle for treatment. Coating the MB with PEG could, moreover, change 
their biodistribution and elimination. The current distribution of MB to the liver could 
make them usable for the detection of cancerous disease in the liver. Distribution to the 
pancreas should be investigated. As a conclusion, more preclinical studies are 
warranted before taking MB to a clinical setting. The characteristics of the polymer 
matrix enabling it to be coupled to ligands and drugs, as well as the ability to attach 
imaging markers to it, make the future possibilities of MB unlimited.  
  
 48 
 
 
   49 
8 ACKNOWLEDGEMENTS 
Many people have supported me during the work with this thesis. I would like to give 
special attention to some of them: 
 
Thank you to my supervisor Professor Moustapha Hassan at Experimental Cancer 
Medicine (ECM), Karolinska Huddinge for his help, support, enthusiasm and flexibility 
to let me work independently in AKM, in collaboration with his research groups, in his 
lab at Novum and for revising my manuscripts and thesis. Thank you to Jennifer 
Usterud for her kind help and support with revising my manuscripts and thesis.  
 
Thank you to my co-supervisor Professor Peter Aspelin at Division of Medical Imaging 
and Technology, Clinical Science, Intervention and Technology (CLINTEC), 
Department of Radiology, Karolinska Huddinge for his help, support and meetings 
throughout this thesis and for allowing me work in the EU project, in the Department of 
Radiology and to independently manage and run the imaging equipment. Thank you to 
Helena Forssell for her friendliness, positive help and support with every administrative 
and sourcing matter.  
 
Thank you to my co-supervisors Professor Kenneth Caidahl and Dr. Björn Gustafsson 
at Clinical Physiology, Karolinska Solna for their help, support and meetings 
throughout the project and for allowing me to continuously work in the EU project and 
in their lab at the Center for Molecular Medicine (CMM).  
 
Thank you to Professor Birgitta Janerot, my mentor and Division Head of Medical 
Imaging and Technology at CLINTEC, Karolinska Huddinge for her support and 
positive spirits and for allowing me to work in the Department.  
 
Thank you to Dr. Torkel Brismar at the Division of Medical Imaging and Technology, 
CLINTEC, Department of Radiology, Karolinska Huddinge for taking me on as a PhD 
student, introducing me to medical imaging and for letting me work in the EU project, 
the Department of Radiology and in collaboration regarding clinical trials, my studies 
and for revising my manuscripts.  
 
Thank you to Dr. Maria Kristoffersen Wiberg, Head of Department of Radiology, 
Karolinska Huddinge for letting me work in the department. Many thanks to all kind 
and helpful Radiology Nurses, Physicists and Staff at the Radiology and MR 
Department. Especially thanks to Karin Kjellsdotter, Marie Persson-Edsborg, Maria 
Andersson, Kerstin Eriksson, Karin Tellin, Hassan Ataei-Chegeni, Karin Lindberg, 
Eliisa Asp, Soroush Sohrabian, Pia Dahlberg, Dr. Nikolaos Kartalis, Love Erlandsson 
Nordin and Martin Uppman for all their help, support and kindness. 
 
Thank you to Professor Rimma Axelsson and Chief Physicist Leif Svensson for their 
help and support and letting me work in the Department of Nuclear Medicine, 
Karolinska Huddinge. Especially thanks to Berit Jansson for her assistance in the 
 50 
nuclear medicine lab, Annie Olsson, Anna Lundell, Meta Lewander and Dr. David 
Minarik for their assistance with the Nuclear Medicine Imaging equipment. Thank you 
to all helpful and kind Nurses, Physicists and Staff in the Department of Nuclear 
Medicine.  
 
Thank you to Professor Mamoun Muhammed, Dr. Fei Ye, Heba Asem and Ramy Hilal 
El-Sayed at the Division of Functional Materials, School of Information and 
Communication Technology, KTH Kista for a fruitful collaboration regarding 
nanoparticles and their generosity when visiting Kista.  
 
Thank you to the Staff at AKM8, Karolinska Huddinge, Nettan, Mette, Jorge, José, 
Diana and Kristina for all their help and friendliness during these studies. 
 
Thank you to Dr. Raoul Kuiper and Tarja Schröder at the Fenotype Core Facility at 
Karolinska Huddinge for their great help with tissue sectioning and microscopy.  
 
Thank you to the ECM group: Professor Moustapha Hassan, Dr. Manuchehr Abedi-
Valugerdi, Dr. Zuzana Potácová , Dr. Maryam Saghafian, Ibrahim El-Serafi, Mona 
Fares, Maria Cordona, Jose Arteaga, Randa Diab and Svetlanda Pavlova for their 
collaborations and group meetings.  
 
Thank you to Dr. Rainer Heuchel and Dr. Ying Zhao at CLINTEC for running the 
IVIS/µCT equipment and for giving interesting insight into tumor biology.  
 
Thank you to Dr. Jörg Hamm at Perkin Elmer Inc. for his support with the IVIS/µCT 
technology.   
 
Thank you to all my Collaborators in the FP7 EU project 3MICRON: 
-Professor Gaio Paradossi, Silvia Margheritelli, Letizia Oddo and Barbara 
Cerroni at UNITV, Rome, Italy for all great collaborations regarding 
microbubbles, kindness and generosity when visiting their lab at UNITV, the 
EU meetings and showing me Rome. 
 
-Dr. habil Lars Dähne, Dr. Claudia Aldenhoven and Dr. Gabriella Egri at 
Surflay Nanotec GmbH, Germany for all great collaborations regarding 
microbubbles and generosity and kindness when visiting Surflay Nanotec, 
during collaboration meetings and the EU meeting in Berlin.  
 
-Dr. Manfred Jugold at DKFZ, Heidelberg Germany for visiting his lab and his 
family’s generosity to invite me to their home.  
 
-Professor Lars-Åke Brodin, Dr. Anna Bjällmark, Dr. Hans Hebert, Dr. Dmitry 
Grishenkov, Dr. Matilda Larsson, Malin Larsson, Satya Kothapalli and Johan 
Härmark at the School of Technology and Health, KTH Flemingsberg for nice 
collaborations and EU meetings.  
   51 
 
Thank you to All my Friends and Family for supporting me before and during the work 
with this thesis:  
Thank you to all my KTH BEST friends, Anna-Karin and Anders, Mattias, Monica and 
Markus, Marianne and Fredrik, Joanna, Elin, Eva for their friendship, fun times and 
new years parties,  understanding about PhD work, support and discussions during both 
positive- and hard times.  
Thank you to Nina and Johan, for many fun times, long time and trusting friendship. 
Thank you to my KTH friends Susanna and Jonas, Hedvig and Carl, Kanchana and 
Pakee for their friendship, fun times, introducing me to and understanding about PhD 
work. Thank you to Jenny and Per, Mats and Anja, Anders and Therese, Jenny and 
Anders, Kikki and Christoffer, Peter and Anna, Maria, Ulrika for their friendship and 
sharing nice trips and dinners together.  
Thank you to my American host family, the Fry’s.  
 
Thank you to my Oncle and Wife and my Cousins for childhood memories in the 
archipelago.  
 
To all my Grand Parents, during their life, for inspiring me to explore nature and 
science during my childhood summers out on the island. 
 
Thank you to my Parents- and Brother in Law for their kindness and hospitality in their 
summer places and ski cottage and for baby-sitting during the work with this thesis. To 
all Micke’s family and cousins.  
 
Thank you to my Sister and Husband for fun times during childhood and on.  
 
Warm thank you to my Mother and Father, during his life, for their endless, invaluable 
love and support and for always believing in me and being proud of me. To my late 
Father for his support, good heart and thinking good of everyone. Jag saknar Dig 
Pappa! For his excellent, intelligent speeches on my wedding day and birthdays and for 
the one I know he would have held on my dissertation day; which can be replaced by 
no one. To my parents for all nice times, dinner table discussions, ski vacations, sailing 
and time in the archipelago and for my high school year in Texas. For their great love 
to their grand-children; to go fishing and playing ice-hockey with them and for always 
being able to baby-sit during the work with this thesis.  
 
To my husband Micke for his endless love, compassion and support and for teaching 
me to use the Teflon suite! For always viewing every obstacle I encountered during the 
work with this thesis with ease and his positivism to always quickly find excellent, 
logic solutions and giving me intelligent explanations of people’s and animal’s 
behavior. For many fun times and trips together. To my Sons Emil and Linus for giving 
me all the love I could possibly need from two wonderful, energetic, nice and cute 
boys. For their understanding of my long working hours during evenings and weekends 
and for their support of this work.  
 52 
  
   53 
9 REFERENCES 
 
1. Semelka, R.C. and T.K. Helmberger, Contrast agents for MR imaging of the 
liver. Radiology, 2001. 218(1): p. 27-38. 
2. Babos, M., et al., In vitro evaluation of alternative oral contrast agents for MRI 
of the gastrointestinal tract. European Journal of Radiology, 2008. 65(1): p. 
133-139. 
3. Maravilla, K.R., et al., Contrast enhancement of central nervous system lesions: 
Multicenter intraindividual crossover comparative study of two MR contrast 
agents. Radiology, 2006. 240(2): p. 389-400. 
4. Lin, Y., Z.Y. Chen, and F. Yang, Ultrasound-based multimodal molecular 
imaging and functional ultrasound contrast agents. Curr Pharm Des, 2013. 
19(18): p. 3342-51. 
5. Mitchell, N., et al., Incorporation of paramagnetic, fluorescent and 
PET/SPECT contrast agents into liposomes for multimodal imaging. 
Biomaterials, 2013. 34(4): p. 1179-92. 
6. John, R., et al., Targeted multifunctional multimodal protein-shell microspheres 
as cancer imaging contrast agents. Mol Imaging Biol, 2012. 14(1): p. 17-24. 
7. Sharma, P., et al., Multimodal nanoparticulate bioimaging contrast agents. 
Methods Mol Biol, 2010. 624: p. 67-81. 
8. Frullano, L. and T.J. Meade, Multimodal MRI contrast agents. J Biol Inorg 
Chem, 2007. 12(7): p. 939-49. 
9. Oostendorp, M., et al., Pharmacokinetics of contrast agents targeted to the 
tumor vasculature in molecular magnetic resonance imaging. Contrast Media 
Mol Imaging, 2010. 5(1): p. 9-17. 
10. Lawaczeck, R., G. Jost, and H. Pietsch, Pharmacokinetics of contrast media in 
humans: model with circulation, distribution, and renal excretion. Invest 
Radiol, 2011. 46(9): p. 576-85. 
11. Schuhmann-Giampieri, G., Liver contrast media for magnetic resonance 
imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol, 
1993. 28(8): p. 753-61. 
12. Eloy, R., C. Corot, and J. Belleville, Contrast media for angiography: 
physicochemical properties, pharmacokinetics and biocompatibility. Clin 
Mater, 1991. 7(2): p. 89-197. 
13. Saari, A., Pharmacokinetics of three contrast media in experimental 
pancreatography. Acta Radiol, 1989. 30(1): p. 81-6. 
14. Jensen, L.I., et al., Contrast media for CT. An analysis of the early 
pharmacokinetics. Invest Radiol, 1985. 20(8): p. 867-70. 
15. Gardeur, D., et al., Pharmacokinetics of contrast media: experimental results in 
dog and man with CT implications. J Comput Assist Tomogr, 1980. 4(2): p. 
178-85. 
16. Engelen, A.J., J.F. Rodrigues De Maranda, and E.J. Ariens, Pharmacokinetics 
of renal contrast media. I. Renal excretion processes studied in dogs by the 
stop-flow technique. Invest Radiol, 1973. 8(4): p. 210-8. 
17. Cavalieri, F., et al., Tethering functional ligands onto shell of ultrasound active 
polymeric microbubbles. Biomacromolecules, 2006. 7(2): p. 604-611. 
18. Barrefelt, A.A., et al., Multimodality imaging using SPECT/CT and MRI and 
ligand functionalized 99mTc-labeled magnetic microbubbles. EJNMMI Res, 
2013. 3(1): p. 12. 
 54 
19. Smolensky, E.D., et al., Scaling laws at the nanosize: the effect of particle size 
and shape on the magnetism and relaxivity of iron oxide nanoparticle contrast 
agents. Journal of Materials Chemistry B, 2013. 1(22): p. 2818-2828. 
20. Barrefelt, A., et al., Biodistribution, kinetics, and biological fate of SPION 
microbubbles in the rat. International Journal of Nanomedicine, 2013. 8: p. 
3241-3254. 
21. Brismar, T.B., et al., Magnetite Nanoparticles Can Be Coupled to Microbubbles 
to Support Multimodal Imaging. Biomacromolecules, 2012. 13(5): p. 1390-
1399. 
22. Swindle, M.M., A.C. Smith, and B.J. Hepburn, Swine as models in 
experimental surgery. J Invest Surg, 1988. 1(1): p. 65-79. 
23. Ustuner, E.T., et al., Swine composite tissue allotransplant model for preclinical 
hand transplant studies. Microsurgery, 2000. 20(8): p. 400-6. 
24. Shigeta, T., et al., Transgenic pig expressing the red fluorescent protein 
kusabira-orange as a novel tool for preclinical studies on hepatocyte 
transplantation. Transplant Proc, 2013. 45(5): p. 1808-10. 
25. Thim, T., et al., Familial hypercholesterolaemic downsized pig with human-like 
coronary atherosclerosis: a model for preclinical studies. EuroIntervention, 
2010. 6(2): p. 261-8. 
26. Jewel, K.L., et al., Imaging: magnetic resonance imaging (MRI). J Med Soc N 
J, 1984. 81(10): p. 884-8. 
27. Damadian, R., Field focusing n.m.r. (FONAR) and the formation of chemical 
images in man. Philos Trans R Soc Lond B Biol Sci, 1980. 289(1037): p. 489-
500. 
28. Damadian, R., et al., Human tumors detected by nuclear magnetic resonance. 
Proc Natl Acad Sci U S A, 1974. 71(4): p. 1471-3. 
29. Damadian, R., L. Minkoff, and M. Goldsmith, Whole-body nuclear magnetic 
resonance scanning: n.m.r. studies of tumour cells. Ciba Found Symp, 
1978(67): p. 131-41. 
30. Lauterbur, P.C., NMR imaging in biomedicine. Cell Biophys, 1986. 9(1-2): p. 
211-4. 
31. Lauterbur, P.C., Cancer detection by nuclear magnetic resonance 
zeugmatographic imaging. Cancer, 1986. 57(10): p. 1899-904. 
32. Lauterbur, P.C., Progress in n.m.r. zeugmatography imaging. Philos Trans R 
Soc Lond B Biol Sci, 1980. 289(1037): p. 483-7. 
33. Drost, D.J., et al., Proton magnetic resonance spectroscopy in the brain: report 
of AAPM MR Task Group #9. Med Phys, 2002. 29(9): p. 2177-97. 
34. Chavhan, G.B., et al., Principles, techniques, and applications of T2*-based 
MR imaging and its special applications. Radiographics, 2009. 29(5): p. 1433-
49. 
35. Karaus, A., et al., Black-blood imaging of the human heart using rapid 
stimulated echo acquisition mode (STEAM) MRI. Journal of Magnetic 
Resonance Imaging, 2007. 26(6): p. 1666-1671. 
36. Reed, A.B., The history of radiation use in medicine. J Vasc Surg, 2011. 53(1 
Suppl): p. 3S-5S. 
37. Kojima, C., et al., X-ray computed tomography contrast agents prepared by 
seeded growth of gold nanoparticles in PEGylated dendrimer. Nanotechnology, 
2010. 21(24): p. 245104. 
38. Hutton, B.F., The origins of SPECT and SPECT/CT. Eur J Nucl Med Mol 
Imaging, 2013. 
39. Tapscott, E., First scintillation camera is foundation for modern imaging 
systems. Journal of Nuclear Medicine, 1998. 39(3): p. 15N-+. 
   55 
40. Tapscott, E., Nuclear medicine pioneer: Hal O. Anger. First scintillation 
camera is foundation for modern imaging systems. J Nucl Med, 1998. 39(3): p. 
15N, 19N, 26N-27N. 
41. Cai, J. and F. Li, Single-photon emission computed tomography tracers for 
predicting and monitoring cancer therapy. Curr Pharm Biotechnol, 2013. 14(7): 
p. 693-707. 
42. Hamamura, M.J., et al., Development of an MR-compatible SPECT system 
(MRSPECT) for simultaneous data acquisition. Phys Med Biol, 2010. 55(6): p. 
1563-75. 
43. Misri, R., K. Saatchi, and U.O. Hafeli, Nanoprobes for hybrid SPECT/MR 
molecular imaging. Nanomedicine (Lond), 2012. 7(5): p. 719-33. 
44. Toubert, M.E., et al., Additional Diagnostic Value of Hybrid SPECT-CT 
Systems Imaging in Patients With Differentiated Thyroid Cancer. Am J Clin 
Oncol, 2012. 
45. Vasquez, K.O., C. Casavant, and J.D. Peterson, Quantitative whole body 
biodistribution of fluorescent-labeled agents by non-invasive tomographic 
imaging. PLoS One, 2011. 6(6): p. e20594. 
46. Blanc, F., et al., 99mTc ovalbumin labelled eggs for gastric emptying 
scintigraphy: in-vitro comparison of solid food markers. Nucl Med Commun, 
2005. 26(11): p. 1021-5. 
47. Rollin-Sillaire, A., et al., Contribution of single photon emission computed 
tomography to the differential diagnosis of dementia in a memory clinic. J 
Alzheimers Dis, 2012. 30(4): p. 833-45. 
48. Miziara, J.M., et al., Preoperative nodal staging of non-small cell lung cancer 
using 99mTc-sestamibi spect/ct imaging. Clinics (Sao Paulo), 2011. 66(11): p. 
1901-9. 
49. Glaudemans, A.W., et al., Bone scintigraphy with technetium-
hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement 
in patients with transthyretin-derived systemic amyloidosis. Amyloid, 2014. 
50. Greenwood, J.P., et al., Comparison of Cardiovascular Magnetic Resonance 
and Single-Photon Emission Computed Tomography in Women with Suspected 
Coronary Artery Disease from the CE-MARC Trial. Circulation, 2013. 
51. Ortiz-Arzate, Z., et al., Kit preparation and biokinetics in women of 99mTc-
EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging. Nucl Med Commun, 
2013. 
52. Madru, R., et al., 99mTc-labeled superparamagnetic iron oxide nanoparticles 
for multimodality SPECT/MRI of sentinel lymph nodes. J Nucl Med, 2012. 
53(3): p. 459-63. 
53. Silva, W.E., et al., New homotrinuclear lanthanide complexes: synthesis, 
characterization and spectroscopic study. J Phys Chem A, 2010. 114(37): p. 
10066-75. 
54. Liang, M., et al., Multimodality Nuclear and Fluorescence Tumor Imaging in 
Mice Using a Streptavidin Nanoparticle. Bioconjugate Chemistry, 2010. 21(7): 
p. 1385-1388. 
55. Baselga, J., et al., Lapatinib with trastuzumab for HER2-positive early breast 
cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. 
Lancet, 2012. 379(9816): p. 633-40. 
56. Rijcken, E., et al., ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in 
vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. 
Gut, 2002. 51(4): p. 529-35. 
57. Hua, S., Targeting sites of inflammation: intercellular adhesion molecule-1 as a 
target for novel inflammatory therapies. Front Pharmacol, 2013. 4: p. 127. 
 56 
58. Krasia-Christoforou, T. and T.K. Georgiou, Polymeric theranostics: using 
polymer-based systems for simultaneous imaging and therapy. Journal of 
Materials Chemistry B, 2013. 1(24): p. 3002-3025. 
59. Singh, R.K., et al., Multifunctional hybrid nanocarrier: Magnetic CNTs 
ensheathed with mesoporous silica for drug delivery and imaging system. ACS 
Appl Mater Interfaces, 2014. 
60. Li, S., et al., Novel Multifunctional Theranostic Liposome Drug Delivery 
System: Construction, Characterization, and Multimodality MR, Near-Infrared 
Fluorescent, and Nuclear Imaging. Bioconjug Chem, 2012. 
61. Chen, H.H., et al., MR imaging of biodegradable polymeric microparticles: a 
potential method of monitoring local drug delivery. Magn Reson Med, 2005. 
53(3): p. 614-20. 
62. de Smet, M., et al., SPECT/CT imaging of temperature-sensitive liposomes for 
MR-image guided drug delivery with high intensity focused ultrasound. J 
Control Release, 2013. 169(1-2): p. 82-90. 
63. Li, W.M., S.Y. Chen, and D.M. Liu, In situ doxorubicin-CaP shell formation on 
amphiphilic gelatin-iron oxide core as a multifunctional drug delivery system 
with improved cytocompatibility, pH-responsive drug release and MR imaging. 
Acta Biomater, 2013. 9(2): p. 5360-8. 
64. Shi, J., et al., PEGylated fullerene/iron oxide nanocomposites for photodynamic 
therapy, targeted drug delivery and MR imaging. Biomaterials, 2013. 34(37): p. 
9666-77. 
65. Sun, C., J.S. Lee, and M. Zhang, Magnetic nanoparticles in MR imaging and 
drug delivery. Adv Drug Deliv Rev, 2008. 60(11): p. 1252-65. 
66. Yang, X., et al., Multifunctional stable and pH-responsive polymer vesicles 
formed by heterofunctional triblock copolymer for targeted anticancer drug 
delivery and ultrasensitive MR imaging. ACS Nano, 2010. 4(11): p. 6805-17. 
67. Zhang, L., et al., Multifunctional and degradable zwitterionic nanogels for 
targeted delivery, enhanced MR imaging, reduction-sensitive drug release, and 
renal clearance. Biomaterials, 2011. 32(20): p. 4604-8. 
68. Zhu, L., et al., Multifunctional pH-sensitive superparamagnetic iron-oxide 
nanocomposites for targeted drug delivery and MR imaging. J Control Release, 
2013. 169(3): p. 228-38. 
69. Butoescu, N., et al., Dexamethasone-containing biodegradable 
superparamagnetic microparticles for intra-articular administration: 
physicochemical and magnetic properties, in vitro and in vivo drug release. Eur 
J Pharm Biopharm, 2009. 72(3): p. 529-38. 
70. Butoescu, N., et al., Dexamethasone-containing PLGA superparamagnetic 
microparticles as carriers for the local treatment of arthritis. Biomaterials, 
2009. 30(9): p. 1772-80. 
71. Hall, A.P., et al., Comparison of computerized image analysis with traditional 
semiquantitative scoring of Perls' Prussian Blue stained hepatic iron 
deposition. Toxicol Pathol, 2013. 41(7): p. 992-1000. 
72. Sprague, W.S., et al., Hemochromatosis secondary to repeated blood 
transfusions in a dog. Vet Pathol, 2003. 40(3): p. 334-7. 
73. Grishenkov, D., et al., Characterization of Acoustic Properties of Pva-Shelled 
Ultrasound Contrast Agents: Ultrasound-Induced Fracture (Part Ii). 
Ultrasound in Medicine and Biology, 2009. 35(7): p. 1139-1147. 
74. Otani, K. and K. Yamahara, Development of antibody-carrying microbubbles 
based on clinically available ultrasound contrast agent for targeted molecular 
imaging: a preliminary chemical study. Mol Imaging Biol, 2011. 13(2): p. 250-
6. 
   57 
75. Kiessling, F., et al., Ultrasound microbubbles for molecular diagnosis, therapy, 
and theranostics. J Nucl Med, 2012. 53(3): p. 345-8. 
76. Dutta, R.K. and S. Sahu, Development of a novel probe sonication assisted 
enhanced loading of 5-FU in SPION encapsulated pectin nanocarriers for 
magnetic targeted drug delivery system. Eur J Pharm Biopharm, 2012. 82(1): p. 
58-65. 
77. Singh, N., et al., Potential toxicity of superparamagnetic iron oxide 
nanoparticles (SPION). Nano Rev, 2010. 1. 
78. Yu, M.K., et al., Drug-loaded superparamagnetic iron oxide nanoparticles for 
combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl, 2008. 
47(29): p. 5362-5. 
79. Mudshinge, S.R., et al., Nanoparticles: Emerging carriers for drug delivery. 
Saudi Pharmaceutical Journal, 2011. 19(3): p. 129-141. 
80. Xiao, W., et al., Prolonged in vivo circulation time by zwitterionic modification 
of magnetite nanoparticles for blood pool contrast agents. Contrast Media Mol 
Imaging, 2012. 7(3): p. 320-7. 
81. Rosen, J.E., et al., Iron oxide nanoparticles for targeted cancer imaging and 
diagnostics. Nanomedicine, 2012. 8(3): p. 275-90. 
82. El-Dakdouki, M.H., et al., Development of multifunctional hyaluronan-coated 
nanoparticles for imaging and drug delivery to cancer cells. 
Biomacromolecules, 2012. 13(4): p. 1144-51. 
83. Ernsting, M.J., et al., Tumor-targeted drug delivery using MR-contrasted 
docetaxel - carboxymethylcellulose nanoparticles. Biomaterials, 2012. 33(15): 
p. 3931-41. 
84. Cavalieri, F., et al., Stable polymeric microballoons as multifunctional device 
for biomedical uses: Synthesis and characterization. Langmuir, 2005. 21(19): p. 
8758-8764. 
85. Brismar, T.B., et al., Magnetite nanoparticles can be coupled to microbubbles 
to support multimodal imaging. Biomacromolecules, 2012. 13(5): p. 1390-9. 
86. Peyratout, C.S. and L. Dahne, Tailor-made polyelectrolyte microcapsules: from 
multilayers to smart containers. Angew Chem Int Ed Engl, 2004. 43(29): p. 
3762-83. 
87. Morawietz, G., et al., Revised guides for organ sampling and trimming in rats 
and mice--Part 3. A joint publication of the RITA and NACAD groups. Exp 
Toxicol Pathol, 2004. 55(6): p. 433-49. 
88. Kittel, B., et al., Revised guides for organ sampling and trimming in rats and 
mice--Part 2. A joint publication of the RITA and NACAD groups. Exp Toxicol 
Pathol, 2004. 55(6): p. 413-31. 
89. Ruehl-Fehlert, C., et al., Revised guides for organ sampling and trimming in 
rats and mice--part 1. Exp Toxicol Pathol, 2003. 55(2-3): p. 91-106. 
90. Barrefelt, A., et al., Biodistribution, kinetics, and biological fate of SPION 
microbubbles in the rat. Int J Nanomedicine, 2013. 8: p. 3241-54. 
91. Shim, K.M., et al., A Detailed Examination of Pulmonary Uptake of (99m)Tc-
Tin Colloid in Healthy Mature Miniature Pigs. In Vivo, 2009. 23(4): p. 551-
554. 
92. [The European pharmacopeia]. Fortschr Med, 1980. 98(4): p. (150). 
93. Yang, F., et al., Superparamagnetic iron oxide nanoparticle-embedded 
encapsulated microbubbles as dual contrast agents of magnetic resonance and 
ultrasound imaging. Biomaterials, 2009. 30(23-24): p. 3882-3890. 
94. Cai, X., F. Yang, and N. Gu, Applications of magnetic microbubbles for 
theranostics. Theranostics, 2012. 2: p. 103-12. 
 58 
95. Weissleder, R., et al., Superparamagnetic iron oxide: pharmacokinetics and 
toxicity. AJR Am J Roentgenol, 1989. 152(1): p. 167-73. 
96. Majumdar, S., S.S. Zoghbi, and J.C. Gore, Pharmacokinetics of 
superparamagnetic iron-oxide MR contrast agents in the rat. Invest Radiol, 
1990. 25(7): p. 771-7. 
97. Yoshikawa, K., et al., [Clinical application of AMI-25 (superparamagnetic iron 
oxide) for the MR imaging of hepatic tumors: a multicenter clinical phase III 
study]. Nihon Igaku Hoshasen Gakkai Zasshi, 1994. 54(2): p. 137-53. 
98. Stark, D.D., et al., Superparamagnetic iron oxide: clinical application as a 
contrast agent for MR imaging of the liver. Radiology, 1988. 168(2): p. 297-
301. 
99. Moore, A., et al., Tumoral distribution of long-circulating dextran-coated iron 
oxide nanoparticles in a rodent model. Radiology, 2000. 214(2): p. 568-74. 
100. Stephen, Z.R., F.M. Kievit, and M. Zhang, Magnetite Nanoparticles for 
Medical MR Imaging. Mater Today (Kidlington), 2011. 14(7-8): p. 330-338. 
101. Briley-Saebo, K.C., et al., Clearance of iron oxide particles in rat liver: effect of 
hydrated particle size and coating material on liver metabolism. Invest Radiol, 
2006. 41(7): p. 560-71. 
102. Bacon, B.R., et al., Ferrite particles: a new magnetic resonance imaging 
contrast agent. Lack of acute or chronic hepatotoxicity after intravenous 
administration. J Lab Clin Med, 1987. 110(2): p. 164-71. 
103. Olesen, J., et al., Skeletal muscle PGC-1alpha is required for maintaining an 
acute LPS-induced TNFalpha response. PLoS One, 2012. 7(2): p. e32222. 
104. Roth, J., et al., Attenuation of fever and release of cytokines after repeated 
injections of lipopolysaccharide in guinea-pigs. J Physiol, 1994. 477 ( Pt 1): p. 
177-85. 
 
 
 
 
 
 
